

## **VOLUME 57 TABLE OF CONTENTS**

**Volume 57, No. 1**

**February 15, 2007**

---

### **EDITORIALS**

**1 Physical Activity and Knee Osteoarthritis: Answers and Questions**

Marian A. Minor

►See article, page 6

**3 Musings on Participation in Health Research and the Recruitment Process: It Is Not Always About the Numbers**

Monique A. M. Gignac

►See article, page 49

---

### **ORIGINAL ARTICLES**

*Osteoarthritis*

**6 Effect of Recreational Physical Activities on the Development of Knee Osteoarthritis in Older Adults of Different Weights: The Framingham Study**

David T. Felson, Jingbo Niu, Margaret Clancy, Burton Sack, Piran Aliabadi, and Yuqing Zhang

►See editorial, page 1

**13 Prognostic Factors of Progression of Osteoarthritis of the Knee: A Systematic Review of Observational Studies**

J. N. Belo, M. Y. Berger, M. Reijman, B. W. Koes, and S. M. A. Bierma-Zeinstra

**27 A Patient-Centered Perspective on Surgery Avoidance for Hip or Knee Arthritis: Lessons for the Future**

Peri J. Ballantyne, Monique A. M. Gignac, and Gillian A. Hawker

*Pediatric Rheumatology*

**35 Proxy-Reported Health-Related Quality of Life of Patients With Juvenile Idiopathic Arthritis: The Pediatric Rheumatology International Trials Organization Multinational Quality of Life Cohort Study**

Sheila Oliveira, Angelo Ravelli, Angela Pistorio, Esteban Castell, Clara Malattia, Anne Marie Prieur, Claudia Saad-Magalhães, Kevin J. Murray, Sang-Cheol Bae, Rik Joos, Ivan Foeldvari, Carolina Duarte-Salazar, Nico Wulffraat, Pekka Lahdenne, Pavla Dolezalova, Jaime de Inocencio, Florence Kanakoudi-Tsakalidou, Michael Hofer, Irina Nikishina, Huri Ozdogan, Philip J. Hashkes, Jeanne M. Landgraf, Alberto Martini, and Nicolino Ruperto, for the Pediatric Rheumatology International Trials Organization (PRINTO)

**44 Economic Impact of Juvenile Idiopathic Arthritis**

Sasha Bernatsky, Ciaran Duffy, Peter Malleson, Debbie Ehrmann Feldman, Yvan St. Pierre, and Ann E. Clarke

*Systemic Lupus Erythematosus*

**49 Factors Determining Participation in Prevention Trials Among Systemic Lupus Erythematosus Patients: A Qualitative Study**

Karen H. Costenbader, Deborah Brome, Danielle Blanch, Victoria Gall, Elizabeth Karlson, and Matthew H. Liang

►See editorial, page 3

## **VOLUME 57 TABLE OF CONTENTS**

**Volume 57, No. 1**

**February 15, 2007**

---

### **EDITORIALS**

**1 Physical Activity and Knee Osteoarthritis: Answers and Questions**

Marian A. Minor

►See article, page 6

**3 Musings on Participation in Health Research and the Recruitment Process: It Is Not Always About the Numbers**

Monique A. M. Gignac

►See article, page 49

---

### **ORIGINAL ARTICLES**

*Osteoarthritis*

**6 Effect of Recreational Physical Activities on the Development of Knee Osteoarthritis in Older Adults of Different Weights: The Framingham Study**

David T. Felson, Jingbo Niu, Margaret Clancy, Burton Sack, Piran Aliabadi, and Yuqing Zhang

►See editorial, page 1

**13 Prognostic Factors of Progression of Osteoarthritis of the Knee: A Systematic Review of Observational Studies**

J. N. Belo, M. Y. Berger, M. Reijman, B. W. Koes, and S. M. A. Bierma-Zeinstra

**27 A Patient-Centered Perspective on Surgery Avoidance for Hip or Knee Arthritis: Lessons for the Future**

Peri J. Ballantyne, Monique A. M. Gignac, and Gillian A. Hawker

*Pediatric Rheumatology*

**35 Proxy-Reported Health-Related Quality of Life of Patients With Juvenile Idiopathic Arthritis: The Pediatric Rheumatology International Trials Organization Multinational Quality of Life Cohort Study**

Sheila Oliveira, Angelo Ravelli, Angela Pistorio, Esteban Castell, Clara Malattia, Anne Marie Prieur, Claudia Saad-Magalhães, Kevin J. Murray, Sang-Cheol Bae, Rik Joos, Ivan Foeldvari, Carolina Duarte-Salazar, Nico Wulffraat, Pekka Lahdenne, Pavla Dolezalova, Jaime de Inocencio, Florence Kanakoudi-Tsakalidou, Michael Hofer, Irina Nikishina, Huri Ozdogan, Philip J. Hashkes, Jeanne M. Landgraf, Alberto Martini, and Nicolino Ruperto, for the Pediatric Rheumatology International Trials Organization (PRINTO)

**44 Economic Impact of Juvenile Idiopathic Arthritis**

Sasha Bernatsky, Ciaran Duffy, Peter Malleson, Debbie Ehrmann Feldman, Yvan St. Pierre, and Ann E. Clarke

*Systemic Lupus Erythematosus*

**49 Factors Determining Participation in Prevention Trials Among Systemic Lupus Erythematosus Patients: A Qualitative Study**

Karen H. Costenbader, Deborah Brome, Danielle Blanch, Victoria Gall, Elizabeth Karlson, and Matthew H. Liang

►See editorial, page 3

**56 Work Dynamics Among Persons With Systemic Lupus Erythematosus**

Edward Yelin, Laura Trupin, Patricia Katz, Lindsey Criswell, Jinoos Yazdany, JoAnn Gillis, and Peter Panopalis

**64 The Systemic Lupus Erythematosus Tri-Nation Study: Cumulative Indirect Costs**

Pantelis Panopalis, Michelle Petri, Susan Manzi, David A. Isenberg, Caroline Gordon, Jean-Luc Senécal, John R. Penrod, Lawrence Joseph, Yvan St. Pierre, Christian Pineau, Paul R. Fortin, Nurhan Sutcliffe, Jean-Richard Goulet, Denis Choquette, Tamara Grodzicky, John M. Esdaile, Ann E. Clarke, and the Tri-Nation Study Group

*Fibromyalgia***71 Use of Complementary and Alternative Medicine Providers by Fibromyalgia Patients Under Insurance Coverage**

Bonnie K. Lind, William E. Lafferty, Patrick Timothy Tyree, Paula K. Diehr, and David E. Grembowski

**77 Mindfulness Meditation Alleviates Depressive Symptoms in Women With Fibromyalgia: Results of a Randomized Clinical Trial**

Sandra E. Sephton, Paul Salmon, Inka Weissbecker, Christi Ulmer, Andrea Floyd, Katherine Hoover, and Jamie L. Studts

*Systemic Sclerosis***86 Health Values of Patients With Systemic Sclerosis**

Dinesh Khanna, Mansoor Ahmed, Daniel E. Furst, Shaari S. Ginsburg, Grace S. Park, Richard Hornung, and Joel Tsevat

**94 Assessing Disability and Quality of Life in Systemic Sclerosis: Construct Validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey**

François Rannou, Serge Poiraudieu, Alice Berezné, Thierry Baubet, Véronique Le-Guenn, Jean Cabane, Loïc Guillevin, Michel Revel, Jacques Fermanian, and Luc Mouthon

*Gout***103 Validity of Gout Diagnoses in Administrative Data**

Leslie R. Harrold, Kenneth G. Saag, Robert A. Yood, Ted R. Mikuls, Susan E. Andrade, Hassan Fouayzi, Judith Davis, K. Arnold Chan, Marsha A. Raebel, Ann Von Worley, and Richard Platt

**109 Prevalence of the Metabolic Syndrome in Patients With Gout: The Third National Health and Nutrition Examination Survey**

Hyon K. Choi, Earl S. Ford, Chaoyang Li, and Gary Curhan

*Rheumatoid Arthritis***116 Longitudinal Power Doppler Ultrasonographic Assessment of Joint Inflammatory Activity in Early Rheumatoid Arthritis: Predictive Value in Disease Activity and Radiologic Progression**

Esperanza Naredo, Paz Collado, Ana Cruz, Mercedes J. Palop, Félix Cabero, Patricia Richi, Loreto Carmona, and Manuel Crespo

**125 HLA-DRB1 and Persistent Chronic Inflammation Contribute to Cardiovascular Events and Cardiovascular Mortality in Patients With Rheumatoid Arthritis**

Miguel A. Gonzalez-Gay, Carlos Gonzalez-Juanatey, Maria J. Lopez-Diaz, Angela Piñeiro, Carlos Garcia-Porrúa, Jose A. Miranda-Filloy, William E. R. Ollier, Javier Martín, and Javier Llorca

*Ankylosing Spondylitis***133 Evaluation and Validation of the Patient Acceptable Symptom State (PASS) in Patients With Ankylosing Spondylitis**

Walter P. Maksymowich, Rhonda Richardson, Catherine Mallon, Désirée van der Heijde, and Annelies Boonen

*Osteoporosis***140 Barriers in the Management of Glucocorticoid-Induced Osteoporosis**

Jenice Ria S. Guzman-Clark, Meika A. Fang, Mary E. Sehl, Laural Taylor, and Theodore J. Hahn

*Environmental Exposures***147 Cell Markers, Cytokines, and Immune Parameters in Cement Mason Apprentices**

C. Carlsten, A. J. De Roos, J. D. Kaufman, H. Checkoway, M. Wener, and N. Seixas

*Early Oligoarthritis***154 A Randomized Controlled Trial of Early Intervention With Intraarticular Corticosteroids Followed by Sulfasalazine Versus Conservative Treatment in Early Oligoarthritis**

Helena Marzo-Ortega, Michael J. Green, Anne-Maree Keenan, Richard J. Wakefield, Susanna Proudman, and Paul Emery

*Sjögren's Syndrome***161 Characterization of B Cell Lymphoma in Patients With Sjögren's Syndrome and Hepatitis C Virus Infection**

Manuel Ramos-Casals, Luca la Civita, Salvatore de Vita, Roser Solans, Mario Luppi, Francisco Medina, Paola Caramaschi, Patrizia Fadda, Ginevra de Marchi, Armando Lopez-Guillermo, Josep Font, and the SS-HCV Study Group

*Behçet's Disease***171 Epidemiology and Clinical Course of Behçet's Disease in the Reggio Emilia Area of Northern Italy: A Seventeen-Year Population-Based Study**

Carlo Salvarani, Nicolò Pipitone, Maria Grazia Catanoso, Luca Cimino, Bruno Tumiati, PierLuigi Macchioni, GianLuigi Bajocchi, Ignazio Olivieri, and Luigi Boiardi

---

*CASE REPORTS***179 Can Tumor Necrosis Factor  $\alpha$  Blockade Predispose to Severe Babesiosis?**

Babafemi Taiwo, Chin Lee, Deepak Venkat, Siddharth Tambar, and Sarah H. Sutton

**182 Purtscher-Like Retinopathy in a Patient With Adult-Onset Still's Disease and Concurrent Thrombotic Thrombocytopenic Purpura**

Tochi M. Okwuosa, Edward W. Lee, Monika Starosta, Saima Chohan, Suncica Volkov, Michael Flicker, James Curran, Kourous A. Rezaei, and Nadera J. Swiss

---

*LETTERS***186 Contributions of OMERACT to Rheumatic Disease Research**

Jasvinder A. Singh, Daniel H. Solomon, Maxime Dougados, David Felson,  
Gillian Hawker, Patricia Katz, Hal Paulus, Jeffrey Siegel, and Carol Wallace

**186 Statin-Induced Adverse Effects and Malignant Hyperthermia Susceptibility:  
Comment on the Article by Guis et al**

Georgirene Vladutiu

**187 Reply**

S. Guis, J. P. Mattei, D. Figarella-Branger, F. Nicoli, J. F. Pellissier, N. Amabile,  
P. J. Cozzone, Y. Le Fur, G. Kozak-Ribbens, and D. Bendahan

**188 Submissions Invited for Themed Issue of Arthritis Care & Research: Cost and  
Social and Psychological Impact of Rheumatic Diseases**

Volume 57, No. 2

March 15, 2007

---

*EDITORIALS***189 The Horseless Carriage: Moving Forward With the Hybrid ACR**

James R. O'Dell

►See article, page 193

**191 Glucocorticoid-Related Cardiovascular and Cerebrovascular Events in  
Rheumatic Diseases: Myth or Reality?**

Miguel A. Gonzalez-Gay

►See article, page 279

---

*SPECIAL ARTICLE***193 A Proposed Revision to the ACR20: The Hybrid Measure of American College  
of Rheumatology Response**

American College of Rheumatology Committee to Reevaluate Improvement Criteria

►See editorial, page 189

---

*ORIGINAL ARTICLES**Pediatric Rheumatology***203 The Pediatric Rheumatology European Society/American College of  
Rheumatology/European League Against Rheumatism Provisional Classification  
Criteria for Juvenile Systemic Sclerosis**

Francesco Zulian, Patricia Woo, Balu H. Athreya, Ronald M. Laxer,  
Thomas A. Medsger, Jr., Thomas J. A. Lehman, Marco Matucci Cerinic,  
Giorgia Martini, Angelo Ravelli, Ricardo Russo, Ruben Cuttica,  
Sheila Knupp Feitosa de Oliveira, Christopher P. Denton, Franco Cozzi,  
Ivan Foeldvari, and Nicolino Ruperto, for the Pediatric Rheumatology European  
Society/American College of Rheumatology/European League Against Rheumatism  
Ad Hoc Committee on Classification Criteria for Juvenile Systemic Sclerosis

- 213 Sonographic Investigation of the Temporomandibular Joint in Patients With Juvenile Idiopathic Arthritis: A Pilot Study**  
Siegfried Jank, Stephan Haase, Heinrich Strobl, Hartmut Michels, Renate Häfner, Martin Missmann, Gerd Bodner, Erich Mur, and Dominik Schroeder
- 219 Caregiver Recall of Treatment Recommendations in Juvenile Idiopathic Arthritis**  
Mirella De Civita, Debbie Ehrmann Feldman, Garbis A. Meshefedjian, Patricia L. Dobkin, Pete Malleson, and Ciarán M. Duffy
- 226 Perceived Adherence to Prescribed Treatment in Juvenile Idiopathic Arthritis Over a One-Year Period**  
Debbie Ehrmann Feldman, Mirella De Civita, Patricia L. Dobkin, Pete Malleson, Garbis Meshefedjian, and Ciarán M. Duffy
- Rheumatoid Arthritis*
- 234 Agreement Between Patient Report and Medical Record Review for Medications Used for Rheumatoid Arthritis: The Accuracy of Self-Reported Medication Information in Patient Registries**  
Daniel H. Solomon, Margaret Stedman, Andrea Licari, Michael E. Weinblatt, Nancy Maher, and Nancy Shadick
- 240 Effectiveness of the Introduction of an International Classification of Functioning, Disability and Health-Based Rehabilitation Tool in Multidisciplinary Team Care in Patients With Rheumatoid Arthritis**  
John Verhoef, Pieter J. Toussaint, Johanna H. M. Zwetsloot-Schonk, Ferdinand C. Breedveld, Hein Putter, and Theodora P. M. Vliet Vlieland
- 249 Development and Validation of a German Version of the Joint Protection Behavior Assessment in Patients With Rheumatoid Arthritis**  
K. Niedermann, A. Forster, A. Hammond, D. Uebelhart, and R. de Bie
- Measurement of Disease Activity*
- 256 The Disease Activity Score in 28 Joints in Rheumatoid Arthritis and Psoriatic Arthritis Patients**  
Burkhard F. Leeb, Ingrid Andel, Judith Sautner, Christian Fassl, Thomas Nothnagl, and Bernhard Rintelen
- Neonatal Lupus Erythematosus*
- 261 Hydrocephalus and Macrocephaly: New Manifestations of Neonatal Lupus Erythematosus**  
Christina A. Boros, Dawn Spence, Susan Blaser, and Earl D. Silverman
- Osteoarthritis*
- 267 Beliefs About the Causes of Osteoarthritis Among Primary Care Patients**  
A. P. Turner, J. H. Barlow, M. Buszewicz, A. Atkinson, and G. Rait
- Patella Cartilage and Bone*
- 272 Factors Affecting Patella Cartilage and Bone in Middle-Aged Women**  
F. S. Hanna, R. J. Bell, S. R. Davis, A. E. Wluka, A. J. Teichtahl, R. O'Sullivan, and F. M. Ciccuttini

*Polymyalgia Rheumatica*

- 279 Glucocorticoids and Cardiovascular and Cerebrovascular Events in Polymyalgia Rheumatica**

Hilal Maradit Kremers, Megan S. Reinalda, Cynthia S. Crowson, John M. Davis, III, Gene G. Hunder, and Sherine E. Gabriel

►See editorial, page 191

*Psoriatic Arthritis*

- 287 Endothelial Dysfunction in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease or Classic Atherosclerosis Risk Factors**

Carlos Gonzalez-Juanatey, Javier Llorca, Jose A. Miranda-Filloy, Encarnacion Amigo-Diaz, Ana Testa, Carlos Garcia-Porrúa, Javier Martin, and Miguel A. Gonzalez-Gay

*Psychological Aspects of Rheumatic Disease*

- 294 Developing and Testing a Measure of Dyadic Efficacy for Married Women With Rheumatoid Arthritis and Their Spouses**

Katherine Regan Sterba, Robert F. DeVellis, Megan A. Lewis, Donald H. Baucom, Joanne M. Jordan, and Brenda DeVellis

- 303 Relationship Between Appearance and Psychological Distress in Rheumatic Diseases**

Sally M. Monaghan, Louise Sharpe, Fiona Denton, Jo Levy, Leslie Schrieber, and Tom Sensky

*Sjögren's Syndrome*

- 310 Improvement of Sjögren's Syndrome After Two Infusions of Rituximab (Anti-CD20)**

Valérie Devauchelle-Pensec, Yvon Pennec, Johanne Morvan, Jacques-Olivier Pers, Capucine Daridon, Sandrine Jousse-Joulin, Anne Roudaut, Christophe Jamin, Yves Renaudineau, Isabelle Quintin Roué, Béatrice Cochener, Pierre Youinou, and Alain Saraux

*Systemic Sclerosis*

- 318 Pulmonary Involvement in Systemic Sclerosis: Associations With Genetic, Serologic, Sociodemographic, and Behavioral Factors**

Terry A. McNearney, John D. Reveille, Michael Fischbach, Alan W. Friedman, Jeffrey R. Lisse, Niti Goel, Filemon K. Tan, Xiaodong Zhou, Chul Ahn, Carol A. Feghali-Bostwick, Marvin Fritzler, Frank C. Arnett, and Maureen D. Mayes

*Total Joint Arthroplasty*

- 327 Differences in Outcomes of Obese Women and Men Undergoing Primary Total Hip Arthroplasty**

Anne Lübbeke, Richard Stern, Guido Garavaglia, Line Zurcher, and Pierre Hoffmeyer

*Work Disability*

- 335 Musculoskeletal Work Disability for Clinicians: Time Course and Effectiveness of a Specialized Intervention Program by Diagnosis**

Lydia Abásolo, Loreto Carmona, César Hernández-García, Cristina Lajas, Estíbaliz Loza, Margarita Blanco, Gloria Candelas, Benjamín Fernández-Gutiérrez, and Juan A. Jover

---

*CONTRIBUTIONS FROM THE FIELD*

- 343 Confirmation of Administrative Claims-Identified Opportunistic Infections and Other Serious Potential Adverse Events Associated With Tumor Necrosis Factor  $\alpha$  Antagonists and Disease-Modifying Antirheumatic Drugs**  
J. R. Curtis, C. Martin, K. G. Saag, N. M. Patkar, J. Kramer, D. Shatin, J. Allison, and M. M. Braun
- 347 Devic's Syndrome in a Woman With Systemic Lupus Erythematosus: Diagnostic and Therapeutic Implications of Testing for the Neuromyelitis Optica IgG Autoantibody**  
Julius Birnbaum and Douglas Kerr
- 351 Submissions Invited for Themed Issue of *Arthritis Care & Research*: Cost and Social and Psychological Impact of Rheumatic Diseases**

---

*CASE REPORT*

- 352 Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus**  
Venugopal Govindappa, Sarah Hicks, Melvin Wichter, and Meenakshi Jolly

Volume 57, No. 3

April 15, 2007

---

*ORIGINAL ARTICLES**Disability*

- 355 Prevalence and Correlates of Arthritis-Attributable Work Limitation in the US Population Among Persons Ages 18–64: 2002 National Health Interview Survey Data**  
Kristina A. Theis, Louise Murphy, Jennifer M. Hootman, Charles G. Helmick, and Edward Yelin
- 364 Evolution of Disability in Adults With Hip Arthroplasty: A National Longitudinal Study**  
Agnes Dechartres, Isabelle Boutron, Remy Nizard, Serge Poiraudieu, Carine Roy, Jean-François Ravaud, and Philippe Ravaud
- 372 Work Disability Among Two Cohorts of Women With Recent-Onset Rheumatoid Arthritis: A Survival Analysis**  
S. Reisine, J. Fifield, S. Walsh, and D. Dauser

**381 Experiences of Mothers Living With Inflammatory Arthritis**

Catherine L. Backman, Linda Del Fabro Smith, Sharon Smith, Pamela L. Montie, and Melinda Suto

*Osteoarthritis*

- 389 Effect of Anatomic Realignment on Muscle Function During Gait in Patients With Medial Compartment Knee Osteoarthritis**  
Dan K. Ramsey, Lynn Snyder-Mackler, Michael Lewek, William Newcomb, and Katherine S. Rudolph

**398 Full-Limb and Knee Radiography Assessments of Varus-Valgus Alignment and Their Relationship to Osteoarthritis Disease Features by Magnetic Resonance Imaging**

Sakeba N. Issa, Dorothy Dunlop, Alison Chang, Jing Song, Pottumarthi V. Prasad, Ali Guermazi, Charles Peterfy, September Cahue, Meredith Marshall, Dipali Kapoor, Karen Hayes, and Leena Sharma

**407 Physical Activity for Osteoarthritis Management: A Randomized Controlled Clinical Trial Evaluating Hydrotherapy or Tai Chi Classes**

Marlene Fransen, Lillias Nairn, Julie Winstanley, Paul Lam, and John Edmonds

**415 Predictors of Depression in a Sample of 1,021 Primary Care Patients With Osteoarthritis**

Thomas Rosemann, Matthias Backenstrass, Katharina Joest, Andrea Rosemann, Joachim Szecsenyi, and Gunter Laux

**423 The Australian/Canadian Osteoarthritis Hand Index in a Community-Dwelling Population of Older Adults: Reliability and Validity**

Krysia S. Dziedzic, Elaine Thomas, Helen Myers, Susan Hill, and Elaine M. Hay

*Rheumatoid Arthritis***429 Measuring Fatigue in Rheumatoid Arthritis: A Systematic Review of Scales in Use**

S. Hewlett, M. Hehir, and J. R. Kirwan

**440 Evaluation of the Preliminary Definitions of Minimal Disease Activity and Remission in an Early Seropositive Rheumatoid Arthritis Cohort**

Dinesh Khanna, MyungShin Oh, Daniel E. Furst, Veena Ranganath, Richard H. Gold, John T. Sharp, Grace S. Park, Edward C. Keystone, and Harold E. Paulus, for the Western Consortium of Practicing Rheumatologists

**448 Therapy of Patients With Rheumatoid Arthritis: Outcome of Infliximab Failures Switched to Etanercept**

Maya H. Buch, Sarah J. Bingham, Victoria Bejarano, Domini Bryer, Jo White, Paul Emery, Richard Reece, and Mark Quinn

**454 Daily Health Status Registration (Patient Diary) in Patients With Rheumatoid Arthritis: A Comparison Between Personal Digital Assistant and Paper-Pencil Format**

Turid Heiberg, Tore K. Kvien, Øystein Dale, Petter Mowinckel, Gerd J. Aanerud, Ann B. Songe-Møller, Till Uhlig, and Kåre B. Hagen

*Gout***461 Computed Tomography Measurement of Tophus Volume: Comparison With Physical Measurement**

Nicola Dalbeth, Barnaby Clark, Kate Gregory, Gregory D. Gamble, Anthony Doyle, and Fiona M. McQueen

*Low Back Pain***466 A Brief Pain Management Program Compared With Physical Therapy for Low Back Pain: Results From an Economic Analysis Alongside a Randomized Clinical Trial**

D. G. T. Whitehurst, M. Lewis, G. L. Yao, S. Bryan, J. P. Raftery, R. Mullis, and E. M. Hay

*Pediatric Rheumatology*

- 474 Social Functioning and Peer Relationships of Adolescents With Juvenile Fibromyalgia Syndrome**

Susmita Kashikar-Zuck, Anne M. Lynch, T. Brent Graham, Nicole F. Swain, Sara M. Mullen, and Robert B. Noll

*Polymyalgia Rheumatica*

- 481 Usefulness of the Disease Activity Scores for Polymyalgia Rheumatica for Predicting Glucocorticoid Dose Changes: A Study of 243 Scenarios**

Aymeric Binard, Michel De Bandt, Jean-Marie Berthelot, and Alain Saraux, for the Inflammatory Joint Disease Working Group (CRI) of the French Society For Rheumatology

*Psoriatic Arthritis*

- 487 Concepts Important to Patients With Psoriatic Arthritis Are Not Adequately Covered by Standard Measures of Functioning**

Tanja A. Stamm, Valerie Nell, Mona Mathis, Michaela Coenen, Daniel Aletaha, Alarcos Cieza, Gerold Stucki, William Taylor, Josef S. Smolen, and Klaus P. Machold

*Repetitive Strain Injury*

- 495 Work-Related Repetitive Strain Injury and Leisure-Time Physical Activity**

C. R. Ratzlaff, J. H. Gillies, and M. W. Koehoorn

*Spondylarthritis*

- 501 Validation of the Spondyloarthritis Research Consortium of Canada Magnetic Resonance Imaging Spinal Inflammation Index: Is It Necessary to Score the Entire Spine?**

Walter P. Maksymowych, Suhkvinder S. Dhillon, Roy Park, David Salonen, Robert D. Inman, and Robert G. W. Lambert

*Systemic Lupus Erythematosus*

- 508 Impact of Health Maintenance Organizations and Fee-For-Service on Health Care Utilization Among People With Systemic Lupus Erythematosus**

Edward Yelin, Laura Trupin, Patricia Katz, Lindsey A. Criswell, Jinoos Yazdany, JoAnn Gillis, and Peter Panopalis

*Therapeutics*

- 516 Risk of Congestive Heart Failure With Nonsteroidal Antiinflammatory Drugs and Selective Cyclooxygenase 2 Inhibitors: A Class Effect?**

Marie Hudson, Elham Rahme, Hugues Richard, and Louise Pilote

---

*CONTRIBUTIONS FROM THE FIELD*

- 524 Heritability of Raynaud's Phenomenon and Vascular Responsiveness to Cold: A Study of Adult Female Twins**

L. F. Cherkas, F. M. K. Williams, L. Carter, K. Howell, C. M. Black, T. D. Spector, and A. J. MacGregor

- 529 Reduction in Orthopedic Surgery Among Patients With Chronic Inflammatory Joint Disease in Norway, 1994–2004**

B. T. S. Fevang, S. A. Lie, L. I. Havelin, L. B. Engesæter, and O. Furnes

---

**CASE REPORT****533 Calciphylaxis: An Important Imitator of Cutaneous Vasculitis**

Dana Jacobs-Kosmin and Raphael J. DeHoratius

---

**TRAINEE ROUNDS****538 Six Refractory Lupus Patients Treated With Rituximab: A Case Series**

JoAnn Zell Gillis, Maria Dall'Era, Andrew Gross, Jinoos Yazdany, and John Davis

Volume 57, No. 4

May 15, 2007

**543 Introduction to Special Section: Disparities in Rheumatic Diseases**

Edward Yelin and Patricia Katz

---

**EDITORIALS****544 Moving from Identifying to Addressing Health Disparities: A Public Health Perspective**

Teresa J. Brady

**547 Health Disparities in the Rheumatic Diseases**

Agustín Escalante

---

**SPECIAL ARTICLES: DISPARITIES IN RHEUMATIC DISEASES****553 Role of Age, Sex, and Obesity in the Higher Prevalence of Arthritis Among Lower Socioeconomic Groups: A Population-Based Survey**

Lucy Busija, Bruce Hollingsworth, Rachelle Buchbinder, and Richard H. Osborne

**562 Disparities in Total Knee Replacements: A Review**

Robert L. Kane, Timothy Wilt, Maria E. Suarez-Almazor, and Steven S. Fu

**568 Development of a Decision Aid to Address Racial Disparities in Utilization of Knee Replacement Surgery**

Haoling H. Weng, Robert M. Kaplan, W. John Boscardin, Catherine H. MacLean, Irene Y. Lee, Weiling Chen, and John D. Fitzgerald

**576 A Multiethnic, Multicenter Cohort of Patients With Systemic Lupus Erythematosus (SLE) as a Model for the Study of Ethnic Disparities in SLE**

Mónica Fernández, Graciela S. Alarcón, Jaime Calvo-Alén, Rosa Andrade, Gerald McGwin Jr., Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group

**585 Association Between African American Race/Ethnicity and Low Bone Mineral Density in Women With Systemic Lupus Erythematosus**

Chin Lee, Orit Almagor, Dorothy D. Dunlop, Anurekha B. Chadha, Susan Manzi, Stewart Spies, and Rosalind Ramsey-Goldman

**593 Association of Socioeconomic and Demographic Factors With Utilization of Rheumatology Subspecialty Care in Systemic Lupus Erythematosus**

Jinoos Yazdany, JoAnn Zell Gillis, Laura Trupin, Patricia Katz, Pantelis Panopalis, Lindsey A. Criswell, and Edward Yelin

**601 Medicaid and Access to Care Among Persons With Systemic Lupus Erythematosus**

JoAnn Zell Gillis, Jinoos Yazdany, Laura Trupin, Laura Julian, Pantelis Panopalis, Lindsey A. Criswell, Patricia Katz, and Edward Yelin

**608 Biology of the Sex and Age Distribution of Systemic Lupus Erythematosus**

Michael D. Lockshin, on behalf of the Mary Kirkland Center for Lupus Research Consortium

---

*ORIGINAL ARTICLES**Systemic Lupus Erythematosus***612 Incidence of Systemic Lupus Erythematosus in the United Kingdom, 1990–1999**

Emily C. Somers, Sara L. Thomas, Liam Smeeth, W. Marieke Schoonen, and Andrew J. Hall

**619 High Risk of Human Papillomavirus Type 16 Infections and of Development of Cervical Squamous Intraepithelial Lesions in Systemic Lupus Erythematosus Patients**

Rahul Nath, Christine Mant, Jennifer Luxton, Graham Hughes, K. Shanti Raju, Phillip Shepherd, and John Cason

*Osteoarthritis***626 Influence of Familial Factors on Radiologic Disease Progression Over 2 Years in Siblings With Osteoarthritis at Multiple Sites: A Prospective Longitudinal Cohort Study**

Stella A. Botha-Scheepers, Iain Watt, Eline Slagboom, Ingrid Meulenbelt, Frits R. Rosendaal, Ferdinand C. Breedveld, and Margreet Kloppenburg

**633 Validation of a Short Form of the Western Ontario and McMaster Universities Osteoarthritis Index Function Subscale in Hip and Knee Osteoarthritis**

Gabriel Baron, Florence Tubach, Philippe Ravaud, Isabelle Logeart, and Maxime Dougados

*Spondylarthropathy***639 Differences in the Incidence of Flares or New Onset of Inflammatory Bowel Diseases in Patients With Ankylosing Spondylitis Exposed to Therapy With Anti-Tumor Necrosis Factor  $\alpha$  Agents**

J. Braun, X. Baraliakos, J. Listing, J. Davis, D. van der Heijde, H. Haibel, M. Rudwaleit, and J. Sieper

**648 Accuracy of the Diagnoses of Spondylarthritides in Veterans Affairs Medical Center Databases**

Jasvinder A. Singh, Aaron R. Holmgren, Hollis Krug, and Siamak Noorbaloochi

*Joint Pain***656 US National Prevalence and Correlates of Low Back and Neck Pain Among Adults**

Tara W. Strine and Jennifer M. Hootman

**666 Assessing Chronic Joint Pain: Lessons from a Focus Group Study**

Rachael Goberman-Hill, Gillian Woolhead, Fiona MacKichan, Salma Ayis, Susan Williams, and Paul Dieppe

*Rheumatoid Arthritis*

- 672 Comparison of Energy Expenditure from Lifestyle Physical Activities Between Patients With Rheumatoid Arthritis and Healthy Controls**  
Carol A. Mancuso, Melina Rincon, Wendy Sayles, and Stephen A. Paget

- 679 Tolerance and Effectiveness of Anti-Tumor Necrosis Factor  $\alpha$  Therapies in Elderly Patients With Rheumatoid Arthritis: A Population-Based Cohort Study**  
Stéphane Genevay, Axel Finckh, Adrian Ciurea, Anne-Marie Chamot, Diego Kyburz, and Cem Gabay, for the Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis

*Churg-Strauss Syndrome*

- 686 Churg-Strauss Syndrome With Poor-Prognosis Factors: A Prospective Multicenter Trial Comparing Glucocorticoids and Six or Twelve Cyclophosphamide Pulses in Forty-Eight Patients**

Pascal Cohen, Christian Pagnoux, Alfred Mahr, Jean-Pierre Arène, Luc Mouthon, Véronique Le Guern, Marie-Hélène André, Martine Gayraud, David Jayne, Daniel Blöckmans, Jean-François Cordier, and Loïc Guillemin, for the French Vasculitis Study Group

*Inflammatory Myopathy*

- 694 Creatine Supplements in Patients With Idiopathic Inflammatory Myopathies Who Are Clinically Weak After Conventional Pharmacologic Treatment: Six-Month, Double-Blind, Randomized, Placebo-Controlled Trial**

Yuen-Li Chung, Helene Alexanderson, Nicoló Pipitone, Catherine Morrison, Maryam Dastmalchi, Christina Ståhl-Hallengren, Selwyn Richards, E. Louise Thomas, Gavin Hamilton, Jimmy D. Bell, Ingrid E. Lundberg, and David L. Scott

Volume 57, No. 5

June 15, 2007

---

*EDITORIALS*

- 703 Moving Forward With Quality: Pay for Reporting Meets Rheumatology**  
Daniel H. Solomon and Sherine E. Gabriel  
►See article, page 707

- 705 The Effective Use of Questionnaires in Clinical Practice**  
Frederick Wolfe  
►See article, page 723

---

*ORIGINAL ARTICLES**Rheumatoid Arthritis*

- 707 Assessment of American College of Rheumatology Quality Criteria for Rheumatoid Arthritis in a Pre-Quality Criteria Patient Cohort**  
K. L. Kahn, C. H. MacLean, A. L. Wong, L. Z. Rubenstein, H. Liu, D. M. Fitzpatrick, J. O. Harker, W. P. Chen, S. B. Traina, B. S. Mittman, B. H. Hahn, and H. E. Paulus  
►See editorial, page 703

**716 Measuring Disease Activity and Functionality During Pregnancy in Patients With Rheumatoid Arthritis**

Yaël A. de Man, Johanna M. W. Hazes, Fleur E. van de Geijn,  
Catharina Krommenhoek, and Radboud J. E. M. Dolhain

*Measurement Issues***723 Using Rasch Analysis to Compare the Psychometric Properties of the Short Form 36 Physical Function Score and the Health Assessment Questionnaire Disability Index in Patients With Psoriatic Arthritis and Rheumatoid Arthritis**

William J. Taylor and Kathryn M. McPherson  
►See editorial, page 705

**730 Use of Accommodations for Valued Life Activities: Prevalence and Effects on Disability Scores**

Patricia P. Katz and Anne Morris

**738 Arthritis Symptoms, the Work Environment, and the Future: Measuring Perceived Job Strain Among Employed Persons With Arthritis**

Monique A. M. Gignac, Deborah Sutton, and Elizabeth M. Badley

*Therapeutics***748 Do Proton-Pump Inhibitors Confer Additional Gastrointestinal Protection in Patients Given Celecoxib?**

Elham Rahme, Alan N. Barkun, Youssef Toubouti, Alissa Scalera, Sophie Rochon, and Jacques LeLorier

**756 Risk of Tuberculosis in Patients Treated With Tumor Necrosis Factor Antagonists Due to Incomplete Prevention of Reactivation of Latent Infection**

Juan J. Gómez-Reino, Loreto Carmona, and Miguel Ángel Descalzo, for the BIOBADASER Group

**762 Long-Term Treatment With Methotrexate or Tumor Necrosis Factor  $\alpha$  Inhibitors Does Not Increase Epstein-Barr Virus Load in Patients With Rheumatoid Arthritis**

Nathalie Balandraud, Sandrine Guis, Jean Baptiste Meynard, Isabelle Auger, Jean Roudier, and Chantal Roudier

*Rehabilitation and Exercise***768 Benefits of Intensive Resistance Training in Patients With Chronic Polymyositis or Dermatomyositis**

Helene Alexanderson, Maryam Dastmalchi, Mona Esbjörnsson-Liljedahl, Christina H. Opava, and Ingrid E. Lundberg

**778 Cost-Utility Analysis of a Multidisciplinary Job Retention Vocational Rehabilitation Program in Patients With Chronic Arthritis at Risk of Job Loss**

Wilbert B. van den Hout, Petronella D. M. de Buck, and Theodora P. M. Vliet Vlieland

*Osteoarthritis***787 Joint Proprioception, Muscle Strength, and Functional Ability in Patients With Osteoarthritis of the Knee**

M. van der Esch, M. Steultjens, J. Harlaar, D. Knol, W. Lems, and J. Dekker

**794 Estimating the Probability of Radiographic Osteoarthritis in the Older Patient With Knee Pain**

George Peat, Elaine Thomas, Rachel Duncan, Laurence Wood, Ross Wilkie, Jonathan Hill, Elaine M. Hay, and Peter Croft

*Polymyalgia Rheumatica***803 Clinical Outcomes, Quality of Life, and Diagnostic Uncertainty in the First Year of Polymyalgia Rheumatica**

Andrew Hutchings, Jane Hollywood, Donna L. Lamping, Colin T. Pease, Kuntal Chakravarty, Barbara Silverman, Ernest H. S. Choy, David G. I. Scott, Brian L. Hazleman, Brian Bourke, Nagui Gendi, and Bhaskar Dasgupta

**810 The Polymyalgia Rheumatica Activity Score in Daily Use: Proposal for a Definition of Remission**

Burkhard F. Leeb, Bernhard Rintelen, Judith Sautner, Christian Fassl, and Howard A. Bird

*Gout and Hyperuricemia***816 Coffee, Tea, and Caffeine Consumption and Serum Uric Acid Level: The Third National Health and Nutrition Examination Survey**

Hyon K. Choi and Gary Curhan

**822 Quality of Care for Gout in the US Needs Improvement**

Jasvinder A. Singh, James S. Hodges, John P. Toscano, and Steven M. Asch

*Fibromyalgia***830 Responder Criteria for Operant and Cognitive-Behavioral Treatment of Fibromyalgia Syndrome**

Kati Thieme, Dennis C. Turk, and Herta Flor

*Pediatric Rheumatology***837 Clinical Features and Outcome of Pediatric Wegener's Granulomatosis**

J. D. Akikusa, R. Schneider, E. A. Harvey, D. Hebert, P. S. Thorner, R. M. Laxer, and E. D. Silverman

*Systemic Lupus Erythematosus***845 Whole Blood Viscosity and Arterial Thrombotic Events in Patients With Systemic Lupus Erythematosus**

Stephanie Booth, Saima Chohan, James C. Curran, Theodore Garrison, Amanda Schmitz, and Tammy O. Utset

*Self-Management***851 Participation in Patient Self-Management Programs**

Bonnie Bruce, Kate Lorig, and Diana Laurent

*Lumbar Disc Disease***855 Schmorl's Nodes: Common, Highly Heritable, and Related to Lumbar Disc Disease**

F. M. K. Williams, N. J. Manek, P. N. Sambrook, T. D. Spector, and A. J. MacGregor

*Musculoskeletal Injury*

- 861 Early Aggressive Care and Delayed Recovery From Whiplash: Isolated Finding or Reproducible Result?**

Pierre Côté, Sheilah Hogg-Johnson, J. David Cassidy, Linda Carroll, John W. Frank, and Claire Bombardier

*Medical Education*

- 869 Exploring the Use of Videotaped Objective Structured Clinical Examination in the Assessment of Joint Examination Skills of Medical Students**

Pirashanthie Vivekananda-Schmidt, Martyn Lewis, David Coady, Catherine Morley, Lesley Kay, David Walker, and Andrew B. Hassell

---

*CONTRIBUTION FROM THE FIELD*

- 877 Possible Role of Streptococcal Infection in Flares of Juvenile Idiopathic Arthritis**

Judith Barash and Ofra Goldzweig

---

*CASE REPORT*

- 881 Late-Onset Gastrointestinal Pain in Juvenile Dermatomyositis as a Manifestation of Ischemic Ulceration From Chronic Endarteropathy**

Gulnara Mamyrova, David E. Kleiner, Laura James-Newton, Bracha Shaham, Frederick W. Miller, and Lisa G. Rider

---

*LETTER TO THE EDITOR*

- 885 Rheumatologists, Where Are We in the Global Health Picture: A Call to Action**

Michele Meltzer and Christiaan Morssink

- 886 Erratum**

Volume 57, No. 6

August 15, 2007

---

*EDITORIAL*

- 887 Making the Case for Exercise in Children With Juvenile Idiopathic Arthritis: What We Know and Where We Go From Here**

Susan Klepper

► See articles, pages 891, 898, and 905

---

*ORIGINAL ARTICLES**Pediatric Rheumatology*

- 891 Aerobic and Anaerobic Exercise Capacity in Children With Juvenile Idiopathic Arthritis**

M. van Brussel, O. T. H. M. Lelieveld, J. van der Net, R. H. H. Engelbert, P. J. M. Helders, and T. Takken

► See editorial, page 887

**898 Aerobic and Anaerobic Exercise Capacity in Adolescents With Juvenile Idiopathic Arthritis**

Otto T. H. M. Lelieveld, Marco van Brussel, Tim Takken, Ellen van Weert, Miek A. van Leeuwen, and Wineke Armbrust

► See editorial, page 887

**905 Effects of Adherence to Treatment on Short-Term Outcomes in Children With Juvenile Idiopathic Arthritis**

Debbie Ehrmann Feldman, Mirella De Civita, Patricia L. Dobkin, Peter N. Malleson, Garbis Meshefedjian, and Ciarán M. Duffy

► See editorial, page 887

**913 Development and Validation of a New Short and Simple Measure of Physical Function for Juvenile Idiopathic Arthritis**

Giovanni Filocamo, Flavio Sztajnbok, Adriana Cespedes-Cruz, Silvia Magni-Manzoni, Angela Pistorio, Stefania Viola, Nicolino Ruperto, Antonella Buoncompagni, Anna Loy, Alberto Martini, and Angelo Ravelli

**921 Delay in Access to Appropriate Care for Children Presenting With Musculoskeletal Symptoms and Ultimately Diagnosed With Juvenile Idiopathic Arthritis**

H. E. Foster, M. S. Eltringham, L. J. Kay, M. Friswell, M. Abinun, and A. Myers

*Rheumatoid Arthritis*

**928 Treatment of Older Adult Patients Diagnosed With Rheumatoid Arthritis: Improved but Not Optimal**

Gabriela Schmajuk, Sebastian Schneeweiss, Jeffrey N. Katz, Michael E. Weinblatt, Soko Setoguchi, Jerry Avorn, Raisa Levin, and Daniel H. Solomon

**935 Minimal Disease Activity, Remission, and the Long-Term Outcomes of Rheumatoid Arthritis**

Frederick Wolfe, Johannes J. Rasker, Maarten Boers, George A. Wells, and Kaleb Michaud

**943 Predictors of Exercise and Effects of Exercise on Symptoms, Function, Aerobic Fitness, and Disease Outcomes of Rheumatoid Arthritis**

Geri B. Neuberger, Lauren S. Aaronson, Byron Gajewski, Susan E. Embretson, Perri E. Cagle, Janice K. Loudon, and Peggy A. Miller

**953 Antioxidants and Other Novel Cardiovascular Risk Factors in Subjects With Rheumatoid Arthritis in a Large Population Sample**

Paola de Pablo, Thomas Dietrich, and Elizabeth W. Karlson

**963 Using the Health Assessment Questionnaire to Estimate Preference-Based Single Indices in Patients With Rheumatoid Arthritis**

Nick Bansback, Carlo Marra, Aki Tsuchiya, Aslam Anis, Daphne Guh, Tony Hammond, and John Brazier

*Systemic Lupus Erythematosus*

**972 Development and Validation of a Disease-Specific Health-Related Quality of Life Measure, the LupusQoL, for Adults With Systemic Lupus Erythematosus**

Kathleen McElhone, Janice Abbott, Joanna Shelmerdine, Ian N. Bruce, Yasmeen Ahmad, Caroline Gordon, Kate Peers, David Isenberg, Ada Ferenkeh-Koroma, Bridget Griffiths, Mohamed Akil, Peter Maddison, and Lee-Suan Teh

**980 Cross-Cultural Adaptation of the Systemic Lupus Erythematosus Quality of Life Questionnaire Into Chinese**

Kok Ooi Kong, Hsu Juang Ho, Hwee Siew Howe, Bernard Yu Hor Thong, Tsui Yee Lian, Hiok Hee Chng, and Khai Pang Leong, for the Tan Tock Seng Hospital Systemic Lupus Erythematosus Study Group

**986 Using the Short Form 6D, as an Overall Measure of Health, to Predict Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus: XLVII, Results From a Multiethnic US Cohort**

Mónica Fernández, Graciela S. Alarcón, Gerald McGwin, Jr., Martha L. Sanchez, Mandar Apte, Luis M. Vilá, and John D. Reveille, for the LUMINA Study Group

**993 Sociodemographic Associations With Early Disease Damage in Patients With Systemic Lupus Erythematosus**

Glinda S. Cooper, Edward L. Treadwell, E. William St.Clair, Gary S. Gilkeson, and Mary Anne Dooley

**1000 Effectively Measuring Adherence to Medications for Systemic Lupus Erythematosus in a Clinical Setting**

Sri Koneru, Michael Shishov, Avis Ware, Yolanda Farhey, Anne-Barbara Mongey, T. Brent Graham, Murray H. Passo, J. Lawrence Houk, Gloria C. Higgins, and Hermine I. Brunner

**1007 Validity and Reliability of the Siconolfi Step Test for Assessment of Physical Fitness in Patients With Systemic Lupus Erythematosus**

Samuele M. Marcova, Francesco Casanova, Matthew B. Fortes, and Peter J. Maddison

*Physical Therapy and Rehabilitation***1012 Test-Retest Reliability of the Peak Knee Adduction Moment During Walking in Patients With Medial Compartment Knee Osteoarthritis**

Trevor B. Birmingham, Michael A. Hunt, Ian C. Jones, Thomas R. Jenkyn, and J. Robert Giffin

**1018 Influences on Knee Movement Strategies During Walking in Persons With Medial Knee Osteoarthritis**

Laura C. Schmitt and Katherine S. Rudolph

**1027 Efficacy and Cost-Effectiveness of Physiotherapy Following Glenohumeral Joint Distension for Adhesive Capsulitis: A Randomized Trial**

Rachelle Buchbinder, Joanne M. Youd, Sally Green, Alicia Stein, Andrew Forbes, Anthony Harris, Kim Bennell, Simon Bell, and Warwick J. L. Wright

*Total Joint Arthroplasty***1038 Primary Knee and Hip Arthroplasty Among Nonagenarians and Centenarians in the United States**

Eswar Krishnan, James F. Fries, and C. Kent Kwoh

**1043 Comparison of the EuroQol and Short Form 6D in Singapore Multiethnic Asian Knee Osteoarthritis Patients Scheduled for Total Knee Replacement**

Feng Xie, Shu-Chuen Li, Nan Luo, Ngai-Nung Lo, Seng-Jin Yeo, Kuang-Ying Yang, Kok-Yong Fong, and Julian Thumboo

*Ankylosing Spondylitis*

- 1050 Health-Related Quality of Life Outcomes in Patients With Active Ankylosing Spondylitis Treated With Adalimumab: Results From a Randomized Controlled Study**

John C. Davis, Jr., Dennis Revicki, Désirée M. F. van der Heijde, Anne M. Rentz, Robert L. Wong, Hartmut Kupper, and Michelle P. Luo

*Arthritis and Disability*

- 1058 Racial/Ethnic Differences in Activities of Daily Living Disability in Older Adults With Arthritis: A Longitudinal Study**

Jing Song, Huan J. Chang, Manasi Tirotkar, Rowland W. Chang, Larry M. Manheim, and Dorothy D. Dunlop

*Gout*

- 1067 Validation of a Radiographic Damage Index in Chronic Gout**

Nicola Dalbeth, Barnaby Clark, Fiona McQueen, Anthony Doyle, and William Taylor

*Psoriatic Arthritis*

- 1074 High Prevalence of Subclinical Atherosclerosis in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease or Classic Atherosclerosis Risk Factors**

Carlos Gonzalez-Juanatey, Javier Llorca, Encarnacion Amigo-Diaz, Trinidad Dierssen, Javier Martin, and Miguel A. Gonzalez-Gay

*Self-Management*

- 1081 Self-Management Education for Persons With Arthritis: Managing Comorbidity and Eliminating Health Disparities**

Jean Goeppinger, Brian Armstrong, Todd Schwartz, Donald Ensley, and Teresa J. Brady

*Systemic Sclerosis*

- 1089 Depression in Patients With Systemic Sclerosis: A Systematic Review of the Evidence**

Brett D. Thombs, Suzanne S. Taillefer, Marie Hudson, and Murray Baron

---

*CASE REPORTS*

- 1098 Recurrent Spells and Bilateral Internal Carotid Artery Stenosis in a Diabetic Male: A Test of Patient-centred**

Vaidehi Chowdhary, David F. Kallmes, Jimmy Fulgham, Fredric Meyer, and Eric L. Matteson

- 1102 Inflammatory Pseudotumor of the Liver Associated With Rheumatoid Arthritis**

Cesar Díaz-Torné, Javier Narváez, Eugenia De Lama, Marc Diez-García, Jose A. Narváez, Berta Bernad, Roger Llatjos, Joan M. Nolla, and José Valverde

---

**LETTER TO THE EDITOR****1107 Vitamin D Deficiency: Cultural Influence and Physician Responsibility**

Michele Meltzer

Volume 57, No. 7

October 15 2007

---

**EDITORIALS****1109 Musculoskeletal Medicine Educational Reform in the Bone and Joint Decade**

Joseph Bernstein, Toby King, and George V. Lawry

**1112 Classification Criteria for Rheumatic Diseases: Why and How?**

Maxime Dougados and Laure Gossec

►See article, page 1119

**1116 Barriers to the Integration of New Evidence in Medicine: The Importance of Context**

John A. Astin

►See articles, pages 1134, 1143, and 1202

---

**SPECIAL ARTICLE****1119 Classification Criteria in Rheumatic Diseases: A Review of Methodologic Properties**

Sindhu R. Johnson, Oemer-Necmi Goek, Davinder Singh-Grewal, Steven C. Vlad, Brian M. Feldman, David T. Felson, Gillian A. Hawker, Jasvinder A. Singh, and Daniel H. Solomon

► See editorial, page 1112

---

**ORIGINAL ARTICLES***Rheumatoid Arthritis***1134 Effect of Mindfulness-Based Stress Reduction in Rheumatoid Arthritis Patients**

Elizabeth K. Pradhan, Mona Baumgarten, Patricia Langenberg, Barry Handwerger, Adele Kaplan Gilpin, Trish Magyari, Marc C. Hochberg, and Brian M. Berman

►See editorial, page 1116

**1143 Safety and Efficacy of *Ganoderma lucidum* (Lingzhi) and San Miao San Supplementation in Patients With Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial**

Edmund K. Li, Lai-Shan Tam, Chun Kwok Wong, Wai Ching Li, Christopher W. K. Lam, Sissi Wachtel-Galor, Iris F. F. Benzie, Yi Xi Bao, Ping Chung Leung, and Brian Tomlinson

**1151 The Importance of the Disease Process and Disease-Modifying Antirheumatic Drug Treatment in the Development of Septic Arthritis in Patients With Rheumatoid Arthritis**

Christopher J. Edwards, Cyrus Cooper, David Fisher, Max Field, Tjeerd P. van Staa, and Nigel K. Arden

**1158 Finger Tendon Disease in Untreated Early Rheumatoid Arthritis: A Comparison of Ultrasound and Magnetic Resonance Imaging**

R. J. Wakefield, P. J. O'Connor, P. G. Conaghan, D. McGonagle, E. M. A. Hensor, W. W. Gibbon, C. Brown, and P. Emery

*Pediatric Rheumatology***1165 Multicenter Validation of a New Quality of Life Measure in Pediatric Lupus**

L. Nandini Moorthy, Margaret G. E. Peterson, Maria Baratelli, Melanie J. Harrison, Karen B. Onel, Elizabeth C. Chalom, Kathleen Haines, Philip J. Hashkes, and Thomas J. A. Lehman

**1174 Initial Validation of the Pediatric Automated Neuropsychological Assessment Metrics for Childhood-Onset Systemic Lupus Erythematosus**

Hermine I. Brunner, Natasha M. Ruth, April German, Shannen Nelson, Murray H. Passo, Tresa Roebuck-Spencer, Jun Ying, and Douglas Ris

**1183 Predictability of the Clinical Course of Juvenile Dermatomyositis Based on Initial Muscle Biopsy: A Retrospective Study of 72 Patients**

L. Miles, K. E. Bove, D. Lovell, J. C. Wargula, H. Bukulmez, M. Shao, S. Salisbury, and J. A. Bean

**1192 International Consensus on a Proposed Score System for Muscle Biopsy Evaluation in Patients With Juvenile Dermatomyositis: A Tool for Potential Use in Clinical Trials**

Lucy R. Wedderburn, Hemlata Varsani, Charles K. C. Li, Katy R. Newton, Anthony A. Amato, Brenda Banwell, Kevin E. Bove, Andrea M. Corse, Alison Emslie-Smith, Brian Harding, Jessica Hoogendijk, Ingrid E. Lundberg, Suey Marie, Carlo Minetti, Inger Nennesmo, Elisabeth J. Rushing, Caroline Sewry, Susan C. Charman, Clarissa A. Pilkington, and Janice L. Holton, on behalf of the UK Juvenile Dermatomyositis Research Group

**1202 The Effects of Vigorous Exercise Training on Physical Function in Children With Arthritis: A Randomized, Controlled, Single-Blinded Trial**

Davinder Singh-Grewal, Jane Schneiderman-Walker, Virginia Wright, Oded Bar-Or, Joseph Beyene, Hiran Selvadurai, Bonnie Cameron, Ronald M. Laxer, Rayfel Schneider, Earl D. Silverman, Lynn Spiegel, Shirley Tse, Claire Leblanc, Janice Wong, Samantha Stephens, and Brian M. Feldman

*Rehabilitation***1211 Clinical Effectiveness of a Rehabilitation Program Integrating Exercise, Self-Management, and Active Coping Strategies for Chronic Knee Pain: A Cluster Randomized Trial**

M. V. Hurley, N. E. Walsh, H. L. Mitchell, T. J. Pimm, A. Patel, E. Williamson, R. H. Jones, P. A. Dieppe, and B. C. Reeves

**1220 Economic Evaluation of a Rehabilitation Program Integrating Exercise, Self-Management, and Active Coping Strategies for Chronic Knee Pain**

M. V. Hurley, N. E. Walsh, H. L. Mitchell, T. J. Pimm, E. Williamson, R. H. Jones, B. C. Reeves, P. A. Dieppe, and A. Patel

*Osteoarthritis***1230 Mapping Hand Functioning in Hand Osteoarthritis: Comparing Self-Report Instruments With a Comprehensive Hand Function Test**

Tanja Stamm, Mona Mathis, Daniel Aletaha, Margreet Kloppenburg, Klaus Machold, and Josef Smolen

**1238 Improving Osteoarthritis Detection in the Community: Pharmacist Identification of New, Diagnostically Confirmed Osteoarthritis**

Carlo A. Marra, Jolanda Cibere, Ross T. Tsuyuki, Judith A. Soon, John M. Esdaile, Louise Gastonguay, Bridgette Oteng, Patrick Embley, Lindsey Colley, Gilbert Enenajor, and Roelof Kok

**1245 Long-Term Effectiveness of Exercise Therapy in Patients With Osteoarthritis of the Hip or Knee: A Systematic Review**

Martijn F. Pisters, Cindy Veenhof, Nico L. U. van Meeteren, Raymond W. Ostelo, Dinny H. de Bakker, François G. Schellevis, and Joost Dekker

**1254 Relationship Between Pain and Medial Knee Joint Loading in Mild Radiographic Knee Osteoarthritis**

Laura E. Thorp, Dale R. Sumner, Markus A. Wimmer, and Joel A. Block

**1261 Effect of Physical Activity on Articular Knee Joint Structures in Community-Based Adults**

Tina L. Racunica, Andrew J. Teichtahl, Yuanyuan Wang, Anita E. Wluka, Dallas R. English, Graham G. Giles, Richard O'Sullivan, and Flavia M. Cicuttini

*Work Disability***1269 Problems Faced at Work Due to Inflammatory Arthritis: New Insights Gained From Understanding Patients' Perspective**

Diane Lacaille, Margaret A. White, Catherine L. Backman, and Monique A. M. Gignac

*Scleroderma***1280 Development of a Preliminary Scleroderma Gastrointestinal Tract 1.0 Quality of Life Instrument**

Dinesh Khanna, Ron D. Hays, Grace S. Park, Yolanda Braun-Moscovici, Maureen D. Mayes, Terry A. McNearney, Vivien Hsu, Philip J. Clements, and Daniel E. Furst

*Systemic Lupus Erythematosus***1287 Concepts Important to Persons With Systemic Lupus Erythematosus and Their Coverage By Standard Measures of Disease Activity and Health Status**

Tanja A. Stamm, Bettina Bauernfeind, Michaela Coenen, Eva Feierl, Mona Mathis, Gerold Stucki, Josef S. Smolen, Klaus P. Machold, and Martin Aringer

*Vasculitis***1296 Development and Initial Evaluation of a Measure of Self-Management for Adults With Antineutrophil Cytoplasmic Antibody-Associated Small-Vessel Vasculitis**

Carolyn T. Thorpe, Robert F. Devellis, Megan A. Lewis, Susan J. Blalock, Susan L. Hogan, and Brenda M. Devellis

*Polymyositis/Dermatomyositis***1303 Effect of Physical Training on the Proportion of Slow-Twitch Type I Muscle Fibers, a Novel Nonimmune-Mediated Mechanism for Muscle Impairment in Polymyositis or Dermatomyositis**

Maryam Dastmalchi, Helene Alexanderson, Ingela Loell, Marcus Ståhlberg, Kristian Borg, Ingrid E. Lundberg, and Mona Esbjörnsson

*Low Back Pain*

- 1311 High-Sensitivity C-Reactive Protein in Chronic Low Back Pain With Vertebral End-Plate Modic Signal Changes**

François Rannou, Walid Ouanes, Isabelle Boutron, Bianca Lovisi, Fouad Fayad, Yann Macé, Didier Borderie, Henri Guerini, Serge Poiraudieu, and Michel Revel

*Miscellaneous*

- 1316 Absence of Histologic Evidence of Synovitis in Patients With Gulf War Veterans' Illness With Joint Pain**

C. Diaz-Torne, H. R. Schumacher, X. Yu, C. Gomez-Vaquero, L. Dai, L. X. Chen, G. Clayburne, E. Einhorn, R. M. Sachdeva, J. A. Singh, and F. Pessler

---

*REVIEW ARTICLE*

- 1324 Lowering Serum Uric Acid Levels: What Is the Optimal Target for Improving Clinical Outcomes in Gout?**

Fernando Perez-Ruiz and Frédéric Lioté

---

*CONTRIBUTIONS FROM THE FIELD*

- 1329 Musculoskeletal Reflex Function in the Joint Hypermobility Syndrome**

William R. Ferrell, Nicola Tennant, Ronald H. Baxendale, Marion Kusel, and Roger D. Sturrock

- 1334 Care in Action—Translating Research Into Practice: CARE IV Conference Report**

Maura D. Iversen, Jackie Hill, Anne-Maree Keenan, Linda C. Li, Mike Hurley, and Thea P. M. Vliet Vlieland

---

*EDITOR'S NOTE*

- 1338 Circumstances in Which Publication of Material Previously Published as an "Abstract" Will be Considered Duplicate Publication**

---

*LETTERS TO THE EDITOR*

- 1339 Are the Short Form 36 Physical and Mental Component Summary Scores Useful Measures in Patients With Systemic Sclerosis? Comment on the Article by Rannou et al**

Marie Hudson, Brett Thombs, and Murray Baron

- 1339 Reply**

Serge Poiraudieu, Jacques Fermanian, François Rannou, and Luc Mouthon

- 1340 How Do We Improve Pediatric Rheumatology Training? A UK Perspective: Comment on the Article by Mayer et al**

Sharmila Jandial and Helen Foster

- 1341 Reply**

Christy Sandborg, Michelle L. Mayer, and Laura Brogan

- 1342 Submissions Invited for Themed Issue of Arthritis Care & Research: Disability and Rehabilitation in the Rheumatic Diseases**

Volume 57, No. 8

December 15, 2007

---

**EDITORIALS**

- 1343 Articulating a Justice Ethic for Rheumatology: A Critical Analysis of Disparities in Rheumatic Diseases**

Maya Rom, Joseph J. Fins, and C. Ronald MacKenzie

- 1346 Warfarin and the Antiphospholipid Syndrome: Does One Size Fit All?**

Raj S. Kasthuri and Robert A. S. Roubey

► See article, page 1487

---

**SPECIAL ARTICLES**

- 1348 Measurement of Fatigue in Systemic Lupus Erythematosus: A Systematic Review**

Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue

- 1358 The Rasch Measurement Model in Rheumatology: What Is It and Why Use It? When Should It Be Applied, and What Should One Look for in a Rasch Paper?**

Alan Tennant and Philip G. Conaghan

► See article, page 1363

---

**ORIGINAL ARTICLES***Osteoarthritis*

- 1363 Internal Construct Validity of the Oxford Knee Scale: Evidence From Rasch Measurement**

Philip G. Conaghan, Mark Emerton, and Alan Tennant

► See article, page 1358

- 1368 Prognosis of Hip Pain in General Practice: A Prospective Followup Study**

Annet M. Lievense, Bart W. Koes, Jan A. N. Verhaar, Arthur M. Bohnen, and Sita M. A. Bierma-Zeinstra

- 1375 Long-Term Outcome Following Total Hip Arthroplasty: A Controlled Longitudinal Study**

Janet Cushnaghan, David Coggon, Isabel Reading, Peter Croft, Patricia Byng, Ken Cox, Paul Dieppe, and Cyrus Cooper

- 1381 Factors Associated With Restricted Mobility Outside the Home in Community-Dwelling Adults Ages Fifty Years and Older With Knee Pain: An Example of Use of the International Classification of Functioning to Investigate Participation Restriction**

Ross Wilkie, George Peat, Elaine Thomas, and Peter Croft

- 1390 Case Management of Arthritis Patients in Primary Care: A Cluster-Randomized Controlled Trial**

Thomas Rosemann, Stefanie Joos, Gunter Laux, Jochen Gensichen, and Joachim Szecsenyi

- 1398 Reproducibility of the Measurement of Knee Joint Proprioception in Patients With Osteoarthritis of the Knee**

E. J. Hurkmans, M. van der Esch, R. W. J. G. Ostelo, D. Knol, J. Dekker, and M. P. M. Steultjens

**1404 Health-Related Quality of Life in Women With Symptomatic Hand Osteoarthritis: A Comparison With Rheumatoid Arthritis Patients, Healthy Controls, and Normative Data**

Barbara Slatkowsky-Christensen, Petter Mowinckel, Jon H. Loge, and Tore K. Kvien

**1410 Hyylan Versus Hyaluronic Acid for Osteoarthritis of the Knee: A Systematic Review and Meta-Analysis**

Stephan Reichenbach, Sacha Blank, Anne W. S. Rutjes, Aijing Shang, Elizabeth A. King, Paul A. Dieppe, Peter Jüni, and Sven Trelle

*Rheumatoid Arthritis*

**1419 Delay in Consultation With Specialists for Persons With Suspected New-Onset Rheumatoid Arthritis: A Population-Based Study**

Debbie Ehrmann Feldman, Sasha Bernatsky, Jeannie Haggerty, Karen Leffondré, Pierre Tousignant, Yves Roy, Yongling Xiao, Michel Zummer, and Michal Abrahamowicz

**1426 Influence of -308 A/G Polymorphism in the Tumor Necrosis Factor  $\alpha$  Gene on Etanercept Treatment in Rheumatoid Arthritis**

Sandrine Guis, Nathalie Balandraud, Julien Bouvenot, Isabelle Auger, Eric Toussirot, Daniel Wendling, Jean-Pierre Mattei, Leonor Nogueira, Benedicte Mugnier, Pierre Legeron, Olfert Landt, Guy Serre, Jean Roudier, and Chantal Roudier

**1431 The Risk of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States and the United Kingdom**

Allison L. Smitten, Hyon K. Choi, Marc C. Hochberg, Samy Suissa, Teresa A. Simon, Marcia A. Testa, and K. Arnold Chan

*Pediatric Rheumatology*

**1439 Prevalence of and Annual Ambulatory Health Care Visits for Pediatric Arthritis and Other Rheumatologic Conditions in the United States in 2001–2004**

Jeffrey J. Sacks, Charles G. Helmick, Yao-Hua Luo, Norman T. Ilowite, and Suzanne Bowyer

**1446 Reliability of Exercise Testing and Functional Activity Questionnaires in Children With Juvenile Arthritis**

Samantha Stephens, Davinder Singh-Grewal, Oded Bar-Or, Joseph Beyene, Bonnie Cameron, Claire M. A. LeBlanc, Rayfel Schneider, Jane Schneiderman-Walker, Hiran Selvadurai, Earl Silverman, Lynn Spiegel, Shirley M. L. Tse, Virginia Wright, and Brian M. Feldman

*Systemic Lupus Erythematosus*

**1453 Impact of Memory Impairment on Employment Status in Persons With Systemic Lupus Erythematosus**

Pantelis Panopalis, Laura Julian, Jinoos Yazdany, JoAnn Zell Gillis, Laura Trupin, Aimee Hersh, Lindsey A. Criswell, Patricia Katz, and Edward Yelin

**1461 General and Specific Factors Associated With Severity of Cognitive Impairment in Systemic Lupus Erythematosus**

P. Tomietto, V. Annese, S. D'Agostini, P. Venturini, G. La Torre, S. De Vita, and G. F. Ferraccioli

*Vasculitis***1473 Vasculitides Associated With Malignancies: Analysis of Sixty Patients**

Olivier Fain, Mohamed Hamidou, Patrice Cacoub, Bertrand Godeau, Bertrand Wechsler, Jacques Pariès, Jérôme Stirnemann, Anne-Sophie Morin, Marc Gatfosse, Thomas Hanslik, Nadia Belmatoug, Olivier Blétry, Ramiro Cevallos, Isabelle Delevaux, Evelyne Fisher, Gilles Hayem, Gérard Kaplan, Claire Le Hello, Luc Mouthon, Claire Larroche, Véra Lemaire, Anne-Marie Piette, Jean-Charles Piette, Thierry Ponge, Xavier Puechal, Jérôme Rossert, Françoise Sarrot-Reynauld, Didier Sicard, Jean-Marc Ziza, Marcel-Francis Kahn, and Loïc Guillevin

**1481 Atherosclerosis in Patients With Biopsy-Proven Giant Cell Arteritis**

Carlos Gonzalez-Juanatey, Maria J. Lopez-Diaz, Javier Martin, Javier Llorca, and Miguel A. Gonzalez-Gay

*Antiphospholipid Antibodies***1487 A Systematic Review of Secondary Thromboprophylaxis in Patients With Antiphospholipid Antibodies**

Guillermo Ruiz-Irastorza, Beverley J. Hunt, and Munther A. Khamashta

► See editorial, page 1346

*Chondrocalcinosis***1496 Hypomagnesemia Associated With Chondrocalcinosis: A Cross-Sectional Study**

Pascal Richette, Ghazi Ayoub, Sophie Lahalle, Eric Vicaut, Abdul-Monem Badran, Francisca Joly, Bernard Messing, and Thomas Bardin

*Osteoporosis***1502 Osteoporosis Disease Management for Fragility Fracture Patients: New Understandings Based on Three Years' Experience With an Osteoporosis Care Service**

J. Timothy Harrington and JoEllen Lease

*Polyarteritis Nodosa***1507 High Titer of Anti-Phosphatidylserine-Prothrombin Complex Antibodies in Patients With Cutaneous Polyarteritis Nodosa**

Tamihiro Kawakami, Masahide Yamazaki, Masako Mizoguchi, and Yoshinao Soma

*Polymyalgia Rheumatica***1514 Treatment of Refractory Polymyalgia Rheumatica with Etanercept: An Open Pilot Study**

Maria Grazia Catanoso, Pierluigi Macchioni, Luigi Boiardi, Nicolò Pipitone, and Carlo Salvarani

*Sjögren's Syndrome***1520 Diagnostic and Prognostic Relevance of Neuromuscular Biopsy in Primary Sjögren's Syndrome-Related Neuropathy**

Benjamin Terrier, Catherine Lacroix, Loïc Guillevin, Pierre-Yves Hatron, Robin Dhote, François Maillot, Elisabeth Diot, Françoise Sarrot-Reynauld, Christelle Sordet, Odile Dubourg, Laurence Meyer, Xavier Mariette, and Jacques-Eric Gottenberg, for the Club Rhumatismes et Inflammation

*Still's Disease*

- 1530 Increased Apoptosis of Peripheral Blood Lymphocytes and Its Association With Interleukin-18 in Patients With Active Untreated Adult-Onset Still's Disease**  
Der-Yuan Chen, Tsu-Yi Hsieh, Chia-Wei Hsieh, Fang-Ju Lin, and Joung-Liang Lan

*Disparities*

- 1539 Racial/Ethnic Disparities in Patient-Reported Nonsteroidal Antiinflammatory Drug (NSAID) Risk Awareness, Patient-Doctor NSAID Risk Communication, and NSAID Risk Behavior**  
Rachel B. Fry, Midge N. Ray, Daniel J. Cobaugh, Norman W. Weissman, Catarina I. Kiefe, Richard M. Shewchuk, Kenneth G. Saag, Jeffrey R. Curtis, and Jeroan J. Allison

*Rheumatology Workforce*

- 1546 Subspecialty Choice: Why Did You Become a Rheumatologist?**  
Sharon L. Kolasinski, Anne R. Bass, Gwendolyn F. Kane-Wanger, Bonita S. Libman, Nora Sandorfi, and Tammy Utset

---

*REVIEW ARTICLE*

- 1552 Small-Vessel and Medium-Vessel Vasculitis**  
Philip Seo and John H. Stone

---

*CONTRIBUTIONS FROM THE FIELD*

- 1560 Sensitivity of the Classification of Psoriatic Arthritis Criteria in Early Psoriatic Arthritis**  
Vinod Chandran, Catherine T. Schentag, and Dafna D. Gladman
- 1564 Delay in Imaging Versus Clinical Response: A Rationale for Prolonged Treatment With Anti-Tumor Necrosis Factor Medication in Early Rheumatoid Arthritis**  
Richard J. Wakefield, Jane E. Freeston, Elizabeth M. A. Hensor, Domini Bryer, Mark A. Quinn, and Paul Emery

---

*CASE REPORTS*

- 1568 Short Digits... What's Up?**  
E. H. J. G. Aarntzen and P. Barrera

- 1572 Switching Tumor Necrosis Factor  $\alpha$  Inhibitors in HLA-B27-Associated Severe Heel Enthesitis**  
Ignazio Olivieri, Enrico Scarano, Angela Padula, Salvatore D'Angelo, and Fabrizio Cantini

---

*ERRATA*

- 1574 Omission of Committee Member Name in Article by the American College of Rheumatology Committee to Reevaluate Improvement Criteria (Arthritis Rheum, March 2007) and Omission of Co-Principal Author Statement in Article by Johnson et al (Arthritis Rheum, October 2007)**

---

**LETTER TO THE EDITOR**

- 1575 Potential Treatment of Calciphylaxis With Vitamin K<sub>2</sub>: Comment on the Article  
by Jacobs-Kosmin and DeHoratius**  
Robert Levy

- 1576 Submissions Invited for Themed Issue of Arthritis Care & Research: Disability  
and Rehabilitation in the Rheumatic Diseases**


- 15A ANNOUNCEMENTS**

- 1577 REVIEWERS 2007**

- 
- 1584 VOLUME 57 TABLE OF CONTENTS**

- 
- 1611 AUTHOR INDEX TO VOLUME 57 (2007)**

- 
- 1616 SUBJECT INDEX TO VOLUME 57 (2007)**





## AUTHOR INDEX

*Arthritis Care & Research*, Volume 57, Numbers 1–8, 2007

### A

- Aanerud GJ, 454  
 Aarntzen EHJC, 1568  
 Aaronson LS, 943  
 Abásolo L, 335  
 Abbott J, 972  
 Abinun M, 921  
 Abrahamowicz M, 1419  
 Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue, 1348  
 Ahmad Y, 972  
 Ahmed M, 86  
 Ahn C, 318  
 Akikusa JD, 837  
 Akil M, 972  
 Alarcón GS, 576, 986  
 Aletaha D, 487, 1230  
 Alexander H, 694, 768, 1303  
 Aliabadi P, 6  
 Allison J, 343, 1539  
 Almagor O, 585  
 Amabile N, 187  
 Amato AA, 1192  
 American College of Rheumatology Committee to Reevaluate Improvement Criteria, 193  
 Amigo-Díaz E, 287, 1074  
 Andel I, 256  
 Andrade R, 576  
 Andrade SE, 103  
 André M-H, 686  
 Anis A, 963  
 Annese V, 1461  
 Apté M, 986  
 Arden NK, 1151  
 Arène J-P, 686  
 Aringer M, 1287  
 Armbrust W, 898  
 Armstrong B, 1081  
 Arnett FC, 318  
 Asch SM, 822  
 Astin JA, 1116  
 Athreya BH, 203  
 Atkinson A, 267  
 Auger I, 762, 1426  
 Avorn J, 928  
 Ayis S, 666  
 Ayoub G, 1496

### B

- Backenstrass M, 415  
 Backman CL, 381, 1269  
 Badley EM, 738  
 Badran A-M, 1496  
 Bae S-C, 35  
 Bajocchi G, 171  
 Balandraud N, 762, 1426  
 Ballantyne PJ, 27  
 Bansback N, 963  
 Banwell B, 1192  
 Bao YX, 1143  
 Baraliakos X, 639  
 Barash J, 877  
 Baratelli M, 1165

- Bardin T, 1496  
 Barkun AN, 748  
 Barlow JH, 267  
 Baron G, 633  
 Baron M, 1089, 1339  
 Bar-O 1202, 1446  
 Barrera P, 1568  
 Bass AR, 1546  
 Baubet T, 94  
 Baucom DH, 294  
 Bauerfeind B, 1287  
 Baumgarten M, 1134  
 Baxendale RH, 1329  
 Bean JA, 1183  
 Bejarano V, 448  
 Bell JD, 694  
 Bell RJ, 272  
 Bell S, 1027  
 Belmatoug N, 1473  
 Belo JN, 13  
 Bendahan D, 187  
 Bennell K, 1027  
 Benzie IFF, 1143  
 Berezné A, 94  
 Berger MY, 13  
 Berman BM, 1134  
 Bernad B, 1102  
 Bernatsky S, 44, 1419  
 Bernstein J, 1109  
 Berthelot J-M, 481  
 Beyene J, 1202, 1446  
 Bierma-Zeinstra SMA, 13, 1368  
 Binard A, 481  
 Bingham SJ, 448  
 BIOBADASER Group, 756  
 Bird HA, 810  
 Birmingham TB, 1012  
 Birnbaum J, 347  
 Black CM, 524  
 Blalock SJ, 1296  
 Blanch D, 49  
 Blanco M, 335  
 Blank S, 1410  
 Blaser S, 261  
 Blétry O, 1473  
 Block JA, 1254  
 Blöckmans D, 686  
 Bodner G, 213  
 Boers M, 935  
 Bohnen AM, 1368  
 Boiardi L, 171, 1514  
 Bombardier C, 661  
 Boonen A, 133  
 Booth S, 845  
 Borderie D, 1311  
 Borg K, 1303  
 Boros CA, 261  
 Boscardin WJ, 568  
 Botha-Scheepers SA, 626  
 Bourke B, 803  
 Boutron I, 364, 1311  
 Bouvenot J, 1426  
 Bove KE, 1183, 1192  
 Bowyer S, 1439  
 Brady TJ, 544, 1081  
 Braun J, 639  
 Braun MM, 343  
 Braun-Moscovici Y, 1280

- Brazier J, 963  
 Breedveld FC, 240, 626  
 Brogan L, 1341  
 Brome D, 49  
 Brown C, 1158  
 Bruce B, 851  
 Bruce IN, 972  
 Brunner HI, 1000, 1174  
 Bryan S, 466  
 Bryer D, 448, 1564  
 Buch MH, 448  
 Buchbinder R, 553, 1027  
 Bukulmez H, 1183  
 Buoncompagni A, 913  
 Busija L, 553  
 Buszewicz M, 267  
 Byng P, 1375

### C

- Cabane J, 94  
 Cabero F, 116  
 Cacoub P, 1473  
 Cagle PE, 943  
 Cahue S, 398  
 Calvo-Alén J, 576  
 Cameron B, 1202, 1446  
 Candelas G, 335  
 Cantini F, 1572  
 Caramaschi P, 161  
 Carlsten C, 147  
 Carmona L, 116, 335, 756  
 Carroll L, 861  
 Carter L, 524  
 Casanova F, 1007  
 Cason J, 619  
 Cassidy JD, 861  
 Castell E, 35  
 Catanozo MG, 171, 1514  
 Cerinic MM, 203  
 Cespedes-Cruz A, 913  
 Cevallos R, 1473  
 Chaddha AB, 585  
 Chakravarty K, 803  
 Chalom EC, 1165  
 Chamot A-M, 679  
 Chan KA, 103, 1431  
 Chandran V, 1560  
 Chang A, 398  
 Chang HJ, 1058  
 Chang RW, 1058  
 Charman SC, 1192  
 Checkoway H, 147  
 Chen D-Y, 1530  
 Chen LX, 1316  
 Chen W, 568  
 Chen WP, 707  
 Cherkas LF, 524  
 Chng HH, 980  
 Chohan S, 182, 845  
 Choi HK, 109, 816, 1431  
 Choquette D, 64  
 Chowdhary V, 1098  
 Choy EHS, 803  
 Chung Y-L, 694  
 Cibere J, 1238  
 Cicuttini FM, 272, 1261  
 Cieza A, 487  
 Cimino L, 171

### D

- D'Agostini S, 1461  
 Dai L, 1316  
 Dalbeth N, 461, 1067  
 Dale Ø, 454  
 Dall'Era M, 538  
 D'Angelo S, 1572  
 Daridon C, 310  
 Dasgupta B, 803  
 Dastmalchi M, 694, 768, 1303  
 Dauser D, 372  
 Davis J, 103, 538, 639  
 Davis JC Jr, 1050  
 Davis JM III, 279  
 Davis SR, 272  
 de Bakker DH, 1245  
 De Bandt M, 481  
 de Bie R, 249  
 de Buck PDM, 778  
 De Civita M, 219, 226, 905  
 de Inocencio J, 35  
 De Lama E, 1102  
 de Man YA, 716  
 de Marchi G, 161  
 de Pablo P, 953  
 De Roos AJ, 147  
 De Vita S, 1461  
 de Vita S, 161  
 Dechartres A, 364

- DeHoratius RJ, 533  
 Dekker J, 787, 1245, 1398  
 Delevaux I, 1473  
 Denton CP, 203  
 Denton F, 303  
 Descalzo MÁ, 756  
 Devauchelle-Pensec V, 310  
 DeVellis B, 294, 1296  
 DeVellis RF, 294, 1296  
 Dhillon SS, 501  
 Dhote R, 1520  
 Diaz-Torné C, 1102, 1316  
 Diehr PK, 71  
 Dieppe P, 666, 1211, 1220,  
     1375, 1410  
 Dierssen T, 1074  
 Dietrich T, 953  
 Diez-García M, 1102  
 Diot E, 1520  
 Dobkin PL, 219, 226, 905  
 Dolezalova P, 35  
 Dolhain RJEM, 716  
 Dooley MA, 993  
 Dougados M, 186, 633, 1112  
 Doyle A, 461, 1067  
 Duarte-Salazar C, 35  
 Dubourg O, 1520  
 Duffy C, 44, 219, 226, 905  
 Duncan R, 794  
 Dunlop D, 398, 585, 1058  
 Dziedzic KS, 423
- E**
- Edmonds J, 407  
 Edwards CJ, 1151  
 Ehrmann Feldman D, 44, 219,  
     226, 905, 1419  
 Einhorn E, 1316  
 Eltringham MS, 921  
 Embley P, 1238  
 Embretson SE, 943  
 Emerton M, 1363  
 Emery P, 154, 448, 1158, 1564  
 Emslie-Smith A, 1192  
 Enenajor G, 1238  
 Engelbert RHH, 891  
 Engesæter LB, 529  
 English DR, 1261  
 Ensley D, 1081  
 Esbjörnsson M, 1303  
 Esbjörnsson-Liljedahl M, 768  
 Escalante A, 547  
 Esdaile JM, 64, 1238
- F**
- Fadda P, 161  
 Fain O, 1473  
 Fang MA, 140  
 Farhey Y, 1000  
 Fassl C, 256, 810  
 Fayad F, 1311  
 Feghali-Bostwick CA, 318  
 Feierl E, 1287  
 Feitosa de Oliveira SK, 203  
 Feldman BM, 1119, 1202,  
     1446  
 Felson D, 6, 186, 1119  
 Ferneh-Koroma A, 972  
 Fermanian J, 94, 1339  
 Fernández M, 576, 986  
 Fernández-Gutiérrez B, 335  
 Ferraccioli GF, 1461
- Ferrell WR, 1329  
 Fevang BTS, 529  
 Field M, 1151  
 Fifield J, 372  
 Figarella-Branger D, 187  
 Filocamo G, 913  
 Finckh A, 679  
 Fins JJ, 1343  
 Fischbach M, 318  
 Fisher D, 1151  
 Fisher E, 1473  
 Fitzgerald JD, 568  
 Fitzpatrick DM, 707  
 Flicker M, 182  
 Flor H, 830  
 Floyd A, 77  
 Foeldvari I, 35, 203  
 Fong K-Y, 1043  
 Font J, 161  
 Forbes A, 1027  
 Ford ES, 109  
 Forster A, 249  
 Fortes MB, 1007  
 Fortin PR, 64  
 Foster H, 921, 1340  
 Fouayzi H, 103  
 Frank JW, 861  
 Fransen M, 407  
 Freeston JE, 1564  
 French Vasculitis Study  
     Group, 686  
 Friedman AW, 318  
 Fries JF, 1038  
 Friswell M, 921  
 Fritzler M, 318  
 Fry RB, 1539  
 Fu SS, 562  
 Fulgham J, 1098  
 Furnes O, 529  
 Furst DE, 86, 440, 1280
- G**
- Gabay C, 679  
 Gabriel SE, 279, 703  
 Gajewski B, 943  
 Gall V, 49  
 Gamble CD, 461  
 Garavaglia G, 327  
 Garcia-Porrúa C, 125, 287  
 Gastonguay L, 1238  
 Gatfosse M, 1473  
 Gayraud M, 686  
 Gendi N, 803  
 Geneva S, 679  
 Gensichen J, 1390  
 German A, 1174  
 Gibbon WW, 1158  
 Giffin JR, 1012  
 Gignac MAM, 3, 27, 738, 1269  
 Giles GG, 1261  
 Gilkeson GS, 993  
 Gillies JH, 495  
 Gillis J, 56, 508, 538, 593,  
     601, 1453  
 Gilpin AK, 1134  
 Ginsburg SS, 86  
 Gladman DD, 1560  
 Godeau B, 1473  
 Goek O-N, 1119  
 Goel N, 318  
 Goeppinger J, 1081  
 Gold RH, 440  
 Goldzweig O, 877
- Gómez-Reino JJ, 756  
 Gomez-Vaquero C, 1316  
 Gonzalez-Gay MA, 125, 191,  
     287, 1074, 1481  
 Gonzalez-Juanatey C, 125,  
     287, 1074, 1481  
 Gooberman-Hill R, 666  
 Gordon C, 64, 972  
 Gossec L, 1112  
 Gottenberg JE, 1520  
 Goulet J-R, 64  
 Govindappa V, 352  
 Graham TB, 474, 1000  
 Green MJ, 154  
 Green S, 1027  
 Gregory K, 461  
 Grembowski DE, 71  
 Griffiths B, 972  
 Grodzicky T, 64  
 Gross A, 538  
 Guerini H, 1311  
 Guermazi A, 398  
 Guh D, 963  
 Guillevin L, 94, 686, 1473,  
     1520  
 Guis S, 187, 762, 1426  
 Guzman-Clark JRS, 140
- H**
- Haase S, 213  
 Häfner R, 213  
 Hagen KB, 454  
 Haggerty J, 1419  
 Hahn BH, 707  
 Hahn TJ, 140  
 Haibel H, 639  
 Haines K, 1165  
 Hall AJ, 612  
 Hamidou M, 1473  
 Hamilton G, 694  
 Hammond A, 249  
 Hammond T, 963  
 Handwerger B, 1134  
 Hanna FS, 272  
 Hanslik T, 1473  
 Harding B, 1192  
 Harker JO, 707  
 Harlaar J, 787  
 Harrington JT, 1502  
 Harris A, 1027  
 Harrison MJ, 1165  
 Harrold LR, 103  
 Harvey EA, 837  
 Hashkes PJ, 35, 1165  
 Hassell AB, 869  
 Hatron P-Y, 1520  
 Havelin LI, 529  
 Hawker G, 27, 186, 1119  
 Hay EM, 423, 466, 794  
 Hayem G, 1473  
 Hayes K, 398  
 Hays RD, 1280  
 Hazes JMW, 716  
 Hazleman BL, 803  
 Hebert D, 837  
 Hehir M, 429  
 Heiberg T, 454  
 Helders PJM, 891  
 Helmick CG, 355, 1439  
 Hensor EMA, 1158, 1564  
 Hernández-García C, 335  
 Hersh A, 1453  
 Hewlett S, 429
- I**
- Ilowite NT, 1439  
 Inflammatory Joint Disease  
     Working Group (CRI) of the  
     French Society For  
     Rheumatology, 481  
 Inman RD, 501  
 Isenberg D, 64, 972  
 Issa SN, 398  
 Iversen MD, 1334
- J**
- Jacobs-Kosmin D, 533  
 James-Newton L, 881  
 Jamin C, 310  
 Jandial S, 1340  
 Jank S, 213  
 Jayne D, 686  
 Jenkyn TR, 1012  
 Joest K, 415  
 Johnson SR, 1119  
 Jolly M, 352  
 Joly F, 1496  
 Jones IC, 1012  
 Jones RH, 1211, 1220  
 Joos R, 35  
 Joos S, 1390  
 Jordan JM, 294  
 Joseph L, 64  
 Jousse-Joulin S, 310  
 Jover JA, 335  
 Julian L, 601, 1453  
 Jüni P, 1410
- K**
- Kahn KL, 707  
 Kahn M-F, 1473  
 Kallmes DF, 1098

- Kanakoudi-Tsakalidou F, 35  
 Kane RL, 562  
 Kane-Wanger GF, 1546  
 Kaplan G, 1473  
 Kaplan RM, 568  
 Kapoor D, 398  
 Karlson E, 49, 953  
 Garrison T, 845  
 Kashikar-Zuck S, 474  
 Kasthuri RS, 1346  
 Katz JN, 928  
 Katz P, 56, 186, 508, 543, 593,  
     601, 1453  
 Katz PP, 730  
 Kaufman JD, 147  
 Kawakami T, 1507  
 Kay L, 869, 921  
 Keenan A-M, 154, 1334  
 Kerr D, 347  
 Keystone EC, 440  
 Khamashita MA, 1487  
 Khanna D, 86, 440, 1280  
 Kiefe CI, 1539  
 King EA, 1410  
 King T, 1109  
 Kirwan JR, 429  
 Kleiner DE, 881  
 Klepper S, 887  
 Kloppenburg M, 626, 1230  
 Knol D, 787, 1398  
 Koehoorn MW, 495  
 Koes BW, 13, 1368  
 Kok R, 1238  
 Kolasinski SL, 1546  
 Koneru S, 1000  
 Kong KO, 980  
 Kozak-Ribbens G, 187  
 Kramer J, 343  
 Kremers HM, 279  
 Krishnan E, 1038  
 Krommenhoek C, 716  
 Krug H, 648  
 Kupper H, 1050  
 Kusel M, 1329  
 Kvien TK, 454, 1404  
 Kwoh CK, 1038  
 Kyburz D, 679
- L**
- la Civita L, 161  
 La Torre G, 1461  
 Lacaille D, 1269  
 Lacroix C, 1520  
 Lafferty WE, 71  
 Lahalle S, 1496  
 Lahdenne P, 35  
 Lajas C, 335  
 Lam CKW, 1143  
 Lam P, 407  
 Lambert RGW, 501  
 Lamping DL, 803  
 Lan J-L, 1530  
 Landgraf JM, 35  
 Landt O, 1426  
 Langenberg P, 1134  
 Larroche C, 1473  
 Laurent D, 851  
 Laux G, 415, 1390  
 Lawry GV, 1109  
 Laxer RM, 203, 837, 1202  
 Le Fur Y, 187  
 Le Guern V, 686  
 Le Hello C, 1473
- Lease J, 1502  
 LeBlanc CMA, 1446  
 Leblanc C, 1202  
 Lee C, 179, 585  
 Lee EW, 182  
 Lee IV, 568  
 Leeb BF, 256, 810  
 Leffondré K, 1419  
 Legeron P, 1426  
 Le-Guern V, 94  
 Lehman TJA, 203, 1165  
 Lelièveld OTHM, 891, 898  
 LeLorier J, 748  
 Lemaire V, 1473  
 Lems W, 787  
 Leong KP, 980  
 Leung PC, 1143  
 Levin R, 928  
 Levy J, 303  
 Levy R, 1575  
 Lewek M, 389  
 Lewis M, 466, 869  
 Lewis MA, 294, 1296  
 Li C, 109  
 Li CKC, 1192  
 Li EK, 1143  
 Li LC, 1334  
 Li S-C, 1043  
 Li WC, 1143  
 Lian TY, 980  
 Liang MH, 49  
 Libman BS, 1546  
 Licari A, 234  
 Lie SA, 529  
 Lievense AM, 1368  
 Lin F-J, 1530  
 Lind BK, 71  
 Lioté F, 1324  
 Lisse JR, 318  
 Listing J, 639  
 Liu H, 707  
 Llatjos R, 1102  
 Llorca J, 125, 287, 1074, 1481  
 Lo N-N, 1043  
 Lockshin MD, 608  
 Loell I, 1303  
 Loge JH, 1404  
 Logeart I, 633  
 Lopez-Diaz MJ, 125, 1481  
 Lopez-Guillermo A, 161  
 Loris K, 851  
 Loudon JK, 943  
 Lovell D, 1183  
 Lovisi B, 1311  
 Loy A, 913  
 Loza E, 335  
 Lübbeke A, 327  
 LUMINA Study Group, 576,  
     986  
 Lundberg IE, 694, 768, 1192,  
     1303  
 Luo MP, 1050  
 Luo N, 1043  
 Luo Y-H, 1439  
 Luppi M, 161  
 Luxton J, 619  
 Lynch AM, 474
- M**
- Macchioni P, 171, 1514  
 Macé Y, 1311  
 MacGregor AJ, 524, 855  
 Machold K, 487, 1230, 1287
- MacKenzie CR, 1343  
 MacKichan F, 666  
 MacLean CH, 568, 707  
 Maddison P, 972  
 Maddison PJ, 1007  
 Magni-Manzoni S, 913  
 Magyari T, 1134  
 Maher N, 234  
 Mahr A, 686  
 Maillot F, 1520  
 Maksymowycz WP, 133, 501  
 Malattia C, 35  
 Malleson P, 44, 219, 226, 905  
 Mallon C, 133  
 Mamyrava G, 881  
 Mancuso CA, 672  
 Manek NJ, 855  
 Manheim LM, 1058  
 Mant C, 619  
 Manzi S, 64, 585  
 Marcora SM, 1007  
 Marie S, 1192  
 Mariette X, 1520  
 Marra C, 963, 1238  
 Marshall M, 398  
 Martin C, 343  
 Martin J, 125, 287, 1074, 1481  
 Martini A, 35, 913  
 Martini G, 203  
 Mary Kirkland Center for  
     Lupus Research  
     Consortium, 608  
 Marzo-Ortega H, 154  
 Mathis M, 487, 1230, 1287  
 Mattei JP, 187, 1426  
 Matteson EL, 1098  
 Mayer ML, 1341  
 Mayes MD, 318, 1280  
 McElhone K, 972  
 McGonagle D, 1158  
 McGwin G Jr., 576, 986  
 McNearney TA, 318, 1280  
 McPherson KM, 723  
 McQueen FM, 461, 1067  
 Medina F, 161  
 Medsger TA Jr., 203  
 Meltzer M, 885, 1107  
 Meshefedjian G, 226, 905  
 Meshefedjian GA, 219  
 Messing B, 1496  
 Meulenbelt I, 626  
 Meyer F, 1098  
 Meyer L, 1520  
 Meynard JB, 762  
 Michaud K, 935  
 Michels H, 213  
 Mikuls TR, 103  
 Miles L, 1183  
 Miller FW, 881  
 Miller PA, 943  
 Minetti C, 1192  
 Minor MA, 1  
 Miranda-Filloy JA, 125, 287  
 Missmann M, 213  
 Mitchell HL, 1211, 1220  
 Mittman BS, 707  
 Mizoguchi M, 1507  
 Monaghan SM, 303  
 Mongey A-B, 1000  
 Montie PL, 381  
 Moorthy LN, 1165  
 Morin A-S, 1473  
 Morley C, 869  
 Morris A, 730
- N**
- Morrison C, 694  
 Morssink C, 885  
 Morvan J, 310  
 Mouthon L, 94, 686, 1339,  
     1473  
 Mowinkel P, 454, 1404  
 Mugnier B, 1426  
 Mullen SM, 474  
 Mullis R, 466  
 Mur E, 213  
 Murphy L, 355  
 Murray KJ, 35  
 Myers A, 921  
 Myers H, 423
- O**
- Nairn L, 407  
 Naredo E, 116  
 Narváez J, 1102  
 Narváez JA, 1102  
 Nath R, 619  
 Nell V, 487  
 Nelson S, 1174  
 Nennesmo I, 1192  
 Neuberger GB, 943  
 Newcomb W, 389  
 Newton KR, 1192  
 Nicoli F, 187  
 Niedermann K, 249  
 Nikishina I, 35  
 Niu J, 6  
 Nizard R, 364  
 Nogueira L, 1426  
 Noll RB, 474  
 Nolla JM, 1102  
 Noorbaloochi S, 648  
 Nothnagl T, 256
- P**
- O'Connor PJ, 1158  
 O'Dell JR, 189  
 Oh M, 440  
 Okwuosa TM, 182  
 Oliveira S, 35  
 Olivieri I, 171, 1572  
 Ollier WER, 125  
 Onel KB, 1165  
 Opava CH, 768  
 Osborne RH, 553  
 Ostelo RW, 1245  
 Ostelo RWIG, 1398  
 O'Sullivan R, 272, 1261  
 Oteng B, 1238  
 Ouane W, 1311  
 Ozdogan H, 35
- 1613

- Pediatric Rheumatology International Trials Organization (PRINTO), 35
- Peers K, 972
- Pellissier JF, 187
- Penncic Y, 310
- Penrod JR, 64
- Perez-Ruiz F, 1324
- Pers J-O, 310
- Pessler F, 1316
- Peterfy C, 398
- Peterson MGE, 1165
- Petri M, 64
- Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis, 679
- Piette A-M, 1473
- Piette J-C, 1473
- Pilkington CA, 1192
- Pilote L, 516
- Pimm TJ, 1211, 1220
- Pineau C, 64
- Pifeiro A, 125
- Pipitone N, 171, 694, 1514
- Pisters MF, 1245
- Pistorio A, 35, 913
- Platt R, 103
- Poiraudieu S, 94, 364, 1311, 1339
- Ponge T, 1473
- Pradhan EK, 1134
- Prasad PV, 398
- Prieur AM, 35
- Proudman S, 154
- Puechal X, 1473
- Putter H, 240
- Q**
- Quinn M, 448, 1564
- R**
- Racunica TL, 1261
- Raeber MA, 103
- Raftery JP, 466
- Rahme E, 516, 748
- Rait G, 267
- Raju KS, 619
- Ramos-Casals M, 161
- Ramsey DK, 389
- Ramsey-Goldman R, 585
- Ranganath V, 440
- Rannou F, 94, 1311, 1339
- Rasker JJ, 935
- Ratzlaff CR, 495
- Ravaud J-F, 364
- Ravaud P, 364, 633
- Ravelli A, 35, 203, 913
- Ray MN, 1539
- Reading I, 1375
- Reece R, 448
- Reeves BC, 1211, 1220
- Reichenbach S, 1410
- Reijman M, 13
- Reinalda MS, 279
- Reisine S, 372
- Renaudineau Y, 310
- Rentz AM, 1050
- Reveille JD, 318, 576, 986
- Revel M, 94, 1311
- Revicki D, 1050
- Rezaei KA, 182
- Richard H, 516
- Richards S, 694
- Richardson R, 133
- Richette P, 1496
- Richi P, 116
- Rider LG, 881
- Rincon M, 672
- Rintelen B, 256, 810
- Ris D, 1174
- Rochon S, 748
- Roebuck-Spencer T, 1174
- Rom M, 1343
- Rosemann A, 415
- Rosemann T, 415, 1390
- Rosendaal FR, 626
- Rossert J, 1473
- Roubey RAS, 1346
- Roudaut A, 310
- Roudier C, 762, 1426
- Roudier J, 762, 1426
- Roué IQ, 310
- Roy C, 364
- Roy Y, 1419
- Rubenstein LZ, 707
- Rudolph KS, 389, 1018
- Rudwaleit M, 639
- Ruiz-Irastorza G, 1487
- Rupert N, 35, 203, 913
- Rushing EJ, 1192
- Russo R, 203
- Ruth NM, 1174
- Rutjes AWS, 1410
- S**
- Saad-Magalhães C, 35
- Saag KG, 103, 343, 1539
- Sachdeva RM, 1316
- Sach B, 6
- Sacks JJ, 1439
- Salisbury S, 1183
- Salmon P, 77
- Salonen D, 501
- Salvarani C, 171, 1514
- Sambrook PN, 855
- Sanchez ML, 986
- Sandborg C, 1341
- Sandfori N, 1546
- Saraux A, 310, 481
- Sarrot-Reynauld F, 1473, 1520
- Sautner J, 256, 810
- Sayles W, 672
- Scalera A, 748
- Scarano E, 1572
- Schellevis FG, 1245
- Schentag CT, 1560
- Schmajuk G, 928
- Schmitt LC, 1018
- Schmitz A, 845
- Schneeweiss S, 928
- Schneider R, 837, 1202, 1446
- Schneiderman-Walker J, 1202, 1446
- Schoonen WM, 612
- Schriever L, 303
- Schroeder D, 213
- Schumacher HR, 1316
- Schwartz T, 1081
- Scott DGI, 803
- Scott DL, 694
- Sehl ME, 140
- Seixas N, 147
- Selvadurai H, 1202, 1446
- Senécal J-L, 64
- Sensky T, 303
- Seo P, 1552
- Septon SE, 77
- Serre G, 1426
- Setoguchi S, 928
- Sewry C, 1192
- Shadick N, 234
- Shaham B, 881
- Shang A, 1410
- Shao M, 1183
- Sharma L, 398
- Sharp JT, 440
- Sharpe L, 303
- Shatin D, 343
- Shelmerdine J, 972
- Shepherd P, 619
- Shewchuk RM, 1539
- Shishov M, 1000
- Sicard D, 1473
- Siegel J, 186
- Sieper J, 639
- Silverman B, 803
- Silverman E, 261, 837, 1202, 1446
- Simon TA, 1431
- Singh JA, 186, 648, 822, 1119, 1316
- Singh-Grewal D, 1119, 1202, 1446
- Slagboom E, 626
- Slatkowsky-Christensen B, 1404
- Smeeth L, 612
- Smith LDF, 381
- Smith S, 381
- Smitten AL, 1431
- Smolen J, 487, 1230, 1287
- Snyder-Mackler L, 389
- Solans R, 161
- Solomon DH, 186, 234, 703, 928, 1119
- Soma Y, 1507
- Somers EC, 612
- Song J, 398, 1058
- Songe-Møller AB, 454
- Soon JA, 1238
- Sordet C, 1520
- Spector TD, 524, 855
- Spence D, 261
- Spiegel L, 1202, 1446
- Spies S, 585
- SS-HCV Study Group, 161
- St. Pierre Y, 44, 64
- Stähling M, 1303
- Stähli-Hallengren C, 694
- Stamm T, 487, 1230, 1287
- Starosta M, 182
- St.Clair EW, 993
- Stedman M, 234
- Stein A, 1027
- Stephens S, 1202, 1446
- Sterba KR, 294
- Stern R, 327
- Steultjens MPM, 787, 1398
- Stirnemann J, 1473
- Stone JH, 1552
- Strine TW, 656
- Strobl H, 213
- Stucki G, 487, 1287
- Studs JL, 77
- Sturrock RD, 1329
- Suarrez-Almazor ME, 562
- Suisse S, 1431
- Sumner DR, 1254
- Sutcliffe N, 64
- Suto M, 381
- Sutton D, 738
- Sutton SH, 179
- Swain NF, 474
- Sweiss NJ, 182
- Szecsenyi J, 415, 1390
- Sztajnbok F, 913
- T**
- Taillefer SS, 1089
- Taiwo B, 179
- Takken T, 891, 898
- Tam L-S, 1143
- Tambar S, 179
- Tan Tock Seng Hospital Systemic Lupus Erythematosus Study Group, 980
- Tan FK, 318
- Taylor W, 487, 723, 1067
- Teih L-S, 972
- Teichtahl AJ, 272, 1261
- Tenant A, 1358, 1363
- Tenant N, 1329
- Terrier B, 1520
- Testa A, 287
- Testa MA, 1431
- Theis KA, 355
- Thieme K, 830
- Thomas E, 423, 794, 1381
- Thomas EL, 694
- Thomas SL, 612
- Thombs B, 1089, 1339
- Thong BYH, 980
- Thorner PS, 837
- Thor LE, 1254
- Thorpe CT, 1296
- Thumboo J, 1043
- Tirodkar M, 1058
- Tomietto P, 1461
- Tomlinson B, 1143
- Tosciano JP, 822
- Toubouti Y, 748
- Tousignant P, 1419
- Toussaint PJ, 240
- Toussirot E, 1426
- Traina SB, 707
- Traylor L, 140
- Treadwell EL, 993
- Trelle S, 1410
- Tri-Nation Study Group, 64
- Trupin L, 56, 508, 593, 601, 1453
- Tse S, 1202, 1446
- Tsevat J, 86
- Tsuchiya A, 963
- Tsuyuki RT, 1238
- Tubach F, 633
- Tumiati B, 171
- Turk DC, 830
- Turner AP, 267
- Tyree PT, 71
- U**
- Uebelhart D, 249
- Uhlig T, 454
- UK Juvenile Dermatomyositis Research Group, 1192
- Ulmer C, 77
- Utset T, 845, 1546

- V**
- Valverde J, 1102
  - van Brussel M, 891, 898
  - van de Geijn FE, 716
  - van den Hout WB, 778
  - van der Esch M, 787, 1398
  - van der Heijde D, 133, 639, 1050
  - van der Net J, 391
  - van Leeuwen MA, 898
  - van Meesteren NLU, 1245
  - van Staa TP, 1151
  - van Weert E, 898
  - Varsani H, 1192
  - Veenhof C, 1245
  - Venkat D, 179
  - Venturini P, 1461
  - Verhaar JAN, 1368
  - Verhoef J, 240
  - Vicaut E, 1496
  - Vilá LM, 576, 986
  - Viola S, 913
  - Vivekananda-Schmidt P, 869
  - Vlad SC, 1119
  - Vladutiu G, 186
  - Vlieland TPMV, 778
- W**
- Vliet Vlieland TPM, 240, 1334
  - Volkov S, 182
  - Wachtel-Galor S, 1143
  - Wakefield RJ, 154, 1158, 1564
  - Walker D, 869
  - Wallace C, 186
  - Walsh NE, 1211, 1220
  - Walsh S, 372
  - Wang Y, 1261
  - Ware A, 1000
  - Wargula JC, 1183
  - Watt I, 626
  - Wechsler B, 1473
  - Wedderburn LR, 1192
  - Weinblatt ME, 234, 928
  - Weissbecker I, 77
  - Weissman NW, 1539
  - Wells GA, 935
  - Wendling D, 1426
  - Wener M, 147
  - Weng HH, 568
- Western Consortium of Practicing Rheumatologists,**  
440
- White J, 448
- White MA, 1269
- Whitehurst DGT, 466
- Wichter M, 352
- Wilkie R, 794, 1381
- Williams FMK, 524, 855
- Williams S, 666
- Williamson E, 1211, 1220
- Wilt T, 562
- Wimmer MA, 1254
- Winstanley J, 407
- Wluka AE, 272, 1261
- Wolfe F, 705, 935
- Wong AL, 707
- Wong CK, 1143
- Wong J, 1202
- Wong RL, 1050
- Woo P, 203
- Wood L, 794
- Woolhead G, 666
- Worley AV, 103
- Wright V, 1202, 1446
- Wright WJL, 1027
- Wulffraat N, 35
- X**
- Xiao Y, 1419
  - Xie F, 1043
- Y**
- Yamazaki M, 1507
  - Yang K-Y, 1043
  - Yao GL, 466
  - Yazdany J, 56, 508, 538, 593, 601, 1453
  - Yelin E, 56, 355, 508, 543, 593, 601, 1453
  - Yeo S-J, 1043
  - Ying J, 1174
  - Yood RA, 103
  - You JM, 1027
  - Youinou P, 310
  - Yu X, 1316
- Z**
- Zhang Y, 6
  - Zhou X, 318
  - Ziza J-M, 1473
  - Zulian F, 203
  - Zummer M, 1419
  - Zurcher L, 327
  - Zwetsloot-Schonk JHM, 240

## SUBJECT INDEX

*Arthritis Care & Research*, Volume 57, Numbers 1–8, 2007

### A

- Abstracts, as duplicate publication, 1338  
Access to care. *See also* Health services utilization  
delayed, after musculoskeletal symptom onset in JIA, 921  
disparities in rheumatic disease care, 1343  
new-onset RA, delay in consultation with specialist, 1419  
SLE, Medicaid and disparities in, 601  
ACR. *See* American College of Rheumatology (ACR)  
Activities of daily living (ADLs)  
RA accommodations, disability and, 730  
racial/ethnic differences in disability in older adults with  
arthritis, 1058  
Activity limitations, OA knee pain and mobility restrictions out-  
side home, 1381  
Adalimumab  
AS, effects on health-related quality of life, 1050  
AS flares and new-onset IBD incidence with, 639  
for heel enthesitis in SpA, etanercept vs., 1572  
tuberculosis risk and use of, 756  
Adherence. *See* Treatment adherence  
Adolescents  
JIA, aerobic and anaerobic exercise capacity, 898  
juvenile FM, social functioning and peer relationships in, 474  
Aerobics. *See* Exercise  
African Americans  
decision aid for reducing discrepancies in total knee replace-  
ment, 568  
low BMD in women with SLE, 585  
pulmonary disorders in SSc, GENISOS study, 318  
racial/ethnic disparities in NSAID risk awareness, patient/doc-  
tor communication, and mediating behavior, 1539  
Age factors  
patient beliefs about causes of OA, 267  
SLE, association with early disease damage, 993  
SLE, sexual biology and, 608  
Aging. *See* Older adults  
American College of Rheumatology (ACR)  
classification criteria for rheumatic diseases, 1112  
provisional classification criteria for juvenile SSc, 203  
RA, hybrid criteria for, 189  
RA, proposed revision to ACR20, 193  
RA quality of care criteria, assessment of, 707  
ANCA. *See* Antineutrophil cytoplasmic antibody (ANCA)  
Ankylosing spondylitis (AS). *See also* Spondyloarthritis (SpA)  
adalimumab treatment and health-related quality of life out-  
comes, 1050  
flares and new-onset IBD incidence in anti-TNF therapy, 639  
MRI spinal inflammation index validation, 501  
Patient Acceptable Symptom State in, 133  
Anticardiolipin, in cutaneous polyarteritis nodosa, 1707  
Anticoagulation therapy  
for APS, 1346  
for thrombosis in APS with aPL, 1487  
Antineutrophil cytoplasmic antibody (ANCA)  
small-vessel vasculitis associated with, self-management mea-  
sure for, 1296  
vasculitis associated with, 1552  
Antioxidants, as RA risk factor, 953  
Anti-phosphatidylserine-prothrombin complex (anti-PS/PT) anti-  
bodies, as marker for cutaneous polyarteritis nodosa, 1707  
Antiphospholipid antibodies (aPL)  
in APS and thrombosis, antithrombotic therapy in, 1487  
cognitive impairment in SLE and, 1461  
in cutaneous polyarteritis nodosa, 1507  
international normalized ratio for anticoagulants in APS and,  
1346  
Antiphospholipid syndrome (APS)  
with aPL and thrombosis, therapy for, 1487

- Antiphospholipid syndrome (APS) (*cont'd*)  
warfarin dosage for, 1346

### Anti-TNF

- AS flares and new-onset IBD incidence, 639  
RA, etanercept efficacy following failure of infliximab, 448  
RA, relationship between clinical and imaging remission fol-  
lowing, 1564  
RA, tolerance and effectiveness in elderly patients, 679  
SpA, effects of switching anti-TNF agents for severe heel en-  
thesitis, 1572  
tuberculosis risk of, 756  
Apoptosis, peripheral blood leukocytes and IL-18 in adult-onset  
Still's disease, 1530  
Arthritis. *See also* specific types of arthritis  
CARE IV conference report, 1334  
cost-utility analysis of vocational rehabilitation in, 778  
occupational stress measurement, 738  
pediatric, prevalence and annual ambulatory care visits in US,  
2001–2004, 1439  
socioeconomic factors in health disparities, 553  
Arthritis & Rheumatism, abstracts as duplicate publication, 1338  
Arthritis Impact Measurement Scales (AIMS), depression predic-  
tors in OA, 415  
Arthritis Impact Measurement Scales Short Form (AIMS2-SF)  
OA, case management outcome in primary care, 1390  
OA, hand function measurement, 1230  
Arthritis Self-Help Course, effectiveness of, 1081  
Arthrodesis, use for inflammatory arthritis in Norway, 529  
Arthroplasty. *See* Joint replacement  
AS. *See* Ankylosing spondylitis (AS)  
Assessment. *See also* Cost assessment; Measuring instruments  
chronic joint pain, in focus groups, 666  
disability questionnaires, 705  
RA, ACR quality of care criteria, 707  
tophus volume in gout, CT vs. physical measurement, 461  
videotapes for assessing joint examination skills of medical  
students, 869  
Assistive devices, accommodations for life activities and disabil-  
ity scores in RA, 730  
Atherosclerosis  
in GCA, 1481  
PsA, endothelial dysfunction without clinically evident cardio-  
vascular disease, 287  
PsA, subclinical prevalence in, 1074  
RA, cardiovascular mortality and HLA-DRB1-related inflam-  
mation in, 125  
SLE, factors determining participation in preventive trials in, 49  
Attention, placebo effects in FM, 830  
Australian/Canadian Osteoarthritis Hand Index (AUSCAN)  
for measuring hand function in OA, 1230  
reliability and validity in older adults, 423  
Autoimmune diseases, cell markers, cytokines, and immune pa-  
rameters in cement mason apprentices, 147  
Automated Neuropsychological Assessment Metrics, pediatric  
(Ped-ANAM), validation in childhood-onset SLE, 1174

### B

- B cell lymphoma, SS with hepatitis C infection, characteristics of,  
161  
B cells, rituximab for SS and depletion of, 310  
Babesiosis, TNF $\alpha$  blockade and predisposition to, 179  
Back pain  
brief pain management program vs. physical therapy for, 466  
chronic, high-sensitivity CRP and vertebral end-plate signal  
changes, MRI study, 1311  
prevalence and correlates with neck pain in adults, 656  
Schmorl's nodes and lumbar disc disease, 855  
Behavioral therapy  
FM, mindfulness meditation for depression, 77

- Behavioral therapy (cont'd)**
- FM, outcome predictors, 830
  - Behçet's disease, epidemiology and clinical course, Italian population-based study, 171
  - Biomarkers
    - for cutaneous polyarteritis nodosa, 1707
    - silica exposure in cement mason apprentices, 147
  - Biopsy
    - muscle, international consensus on scoring system for juvenile DM, 1192
    - muscle, for predicting course of juvenile DM, 1183
    - neuromuscular, for SS-related peripheral neuropathy diagnosis, 1520
  - Body image, and psychological distress in rheumatic diseases, 303
  - Body mass index (BMI), patella cartilage volume and bone volume in women, 272
  - Bone marrow, physical activity effects on, 1261
  - Bone mineral density (BMD)
    - in African American women with SLE, 585
    - fragility fractures and osteoporosis, 1502
  - Brachydactyly, hereditary multiple exostosis with JIA and, 1568
  - Button Test, for hand OA functional assessment, 1230
- C**
- Caffeine, intake and serum uric acid, 816
  - Calciphylaxis
    - cutaneous vasculitis vs., 533
    - vitamin K<sub>2</sub> for, 1575
  - Canada, cumulative indirect costs of SLE, 64
  - Canadian Community Health Survey, work-related repetitive stress injury and leisure-time physical activity, 495
  - Cancer, vasculitis characteristics and outcomes associated with, 1473
  - Cardiovascular diseases. *See also* Atherosclerosis
    - congestive heart failure risk factors, NSAIDs vs. COX-2 inhibitors, 516
    - GC-related, in PMR, 279
    - GC-related, in rheumatic diseases, 191
    - in RA, 953
    - RA, HLA-DRB1 and inflammation in, 125
  - Caregivers, recall of JIA treatment recommendations by, 219
  - Carotid arteries, intima-media thickness and atherosclerosis in GCA, 1481
  - Carotid artery stenosis, internal, in diabetic male, 1098
  - Cartilage
    - patella, factors affecting volume and defects in women, 272
    - physical activity effects on knee joint structures in adults, 1261
  - Case management, OA self-management education in primary care, controlled trial, 1390
  - Celecoxib
    - congestive heart failure risk, NSAIDs vs., 516
    - with proton-pump inhibitors, gastrointestinal safety in elderly patients, 748
  - Cerebrovascular disorders
    - GC use and, in PMR, 179
    - whole blood viscosity and arterial thrombosis in SLE, 845
  - Cervical abnormalities, squamous intraepithelial lesions and HPV infection risk in SLE, 619
  - Child Health Questionnaire (CHQ), proxy-reported health-related quality of life in JIA, 35
  - Childhood Health Assessment Questionnaire (C-HAQ)
    - JIA, for physical function assessment, 913
    - JIA, proxy-reported health-related quality of life, 35
    - JIA, reliability of, 1446
  - Children. *See also* Juvenile
    - arthritis and other rheumatic conditions, prevalence and annual ambulatory care visits in US, 2001-2004, 1439
    - delayed access to JIA care after symptom onset, 921
    - exercise capacity in JIA, 891
    - exercise and physical function in JIA, 1202
    - hydrocephalus and macrocephaly in neonatal lupus erythematosus, 261
  - Children. *See also* Juvenile (cont'd)
  - reliability of exercise testing and functional activity questionnaires in JIA, 1446
  - validation of pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) in childhood-onset SLE, 1174
  - WG in, clinical features and outcome, 837
  - Chinese medicine, traditional, safety and efficacy of *Ganoderma lucidum* and San Miao San for RA, 1143
  - Chondrocalcinosis, hypomagnesemia in, 1496
  - Chronic Disease Self-Management Program, effectiveness of, 1081
  - Chronic Illness Job Strain Scale (CIJSS), for arthritis, 738
  - Churg-Strauss syndrome
    - glucocorticoids and adjuvant cyclophosphamide for, 686
    - pathogenesis, 1552
  - Classification of Psoriatic Arthritis (CASPAR) criteria, sensitivity of, 1560
  - Cochin Hand Function Scale (CHFS)
    - in OA, 1230
    - SSc, construct validity, 94, 1339
  - Coffee, consumption and serum uric acid levels, 816
  - Cognitive function
    - pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) validation in childhood-onset SLE, 1174
    - SLE, impairment in, factors affecting severity of, 1461
    - SLE, memory impairment and employment status, 1453
  - Cognitive-behavioral therapy, predictors for FM outcome, 830
  - Cold, Raynaud's phenomenon vascular response in twins, 524
  - Combination therapy
    - glucocorticoids and cyclophosphamide for Churg-Strauss syndrome, 686
    - intraarticular corticosteroids followed by sulfasalazine vs. conservative treatment for oligoarthritis, 154
  - Comorbidity
    - gout and metabolic syndrome, 109
    - hereditary multiple exostosis with JIA and brachydactyly, 1568
    - low back and neck pain in adults, 656
    - self-management education reducing, 1081
  - Complementary and alternative medicine (CAM)
    - Chinese herbal therapy, *Ganoderma lucidum* and San Miao San for RA, 1143
    - insurance coverage and FM patient use of, 71
  - Computed tomography (CT)
    - inflammatory pseudotumor of liver in RA, 1102
    - tophus volume in gout, vs. physical measurement, 461
  - Conferences, CARE IV report, 1334
  - Congestive heart failure, NSAIDs vs. COX-2 inhibitors, risk factors, 516
  - Context, evidence-based medicine and, 1116
  - Coping
    - dyadic efficacy of married women with RA and their spouses, 294
    - in integrated rehabilitation program for knee pain, 1211, 1220
    - parents' perceived adherence to JIA treatment, 226
    - patient avoidance of total joint replacement for hip or knee OA, 27
  - Corticosteroids
    - atherosclerosis in GCA and, 1481
    - etanercept as steroid-sparing agent for refractory PMR, 1514
    - intraarticular, followed by sulfasalazine, vs. conservative treatment for early oligoarthritis, 154
  - Cost assessment
    - cumulative indirect costs of SLE in US, Canada, and UK, 64
  - Enabling Self-Management and Coping with Arthritic Knee Pain through Exercise, economic program evaluation, 1220
  - FM, insurance coverage and use of complementary and alternative medicine providers, 71
  - JIA, economic impact of, 44
  - Cost effectiveness
    - brief pain management program vs. physical therapy for low back pain, 466
    - physical therapy following joint distension for adhesive capsulitis, 1027
    - vocational rehabilitation in chronic arthritis, 778

C-reactive protein (CRP), high-sensitivity, in chronic low back pain, MRI study, 1311  
Creatine supplements vs. exercise, for idiopathic inflammatory myopathies, 694  
Criteria  
classification criteria for rheumatic diseases, 1119  
FM, operant and cognitive-behavioral treatment, 830  
juvenile SSc, provisional classification, 203  
PsA, sensitivity of CASPAR criteria, 1560  
RA, ACR quality of care criteria, 707  
RA, hybrid ACR, 189  
RA, proposed revision to ACR20, 193  
Crohn's disease, administrative claims-identified adverse affects of TNF $\alpha$  antagonists and DMARDs for, 343  
Cross-cultural adaptation, SLEQOL questionnaire, Chinese translation, 980  
CT. *See* Computed tomography (CT)  
Cultural factors, in vitamin D deficiency, 1107  
Cyclooxygenase (COX) inhibitors, congestive heart failure risk vs. NSAIDS, 516  
Cyclophosphamide with glucocorticoids, for Churg-Strauss syndrome, 686  
Cytokines  
RA, levels in *Ganoderma lucidum* and San Miao San herbal therapy, 1143  
silica exposure in cement mason apprentices, 147

## D

Databases  
administrative claims-identified adverse affects of TNF $\alpha$  antagonists and DMARDs, 343  
VA, accuracy of SpA diagnostic codes, 648  
validity of gout diagnoses in administrative data, 103  
Decision making  
patient avoidance of total joint replacement for hip or knee OA, 27  
SLE patient participation in atherosclerosis prevention trials, 49  
Delivery of health care  
gout, physician adherence to quality of care indicators, 822  
JIA, delayed access to care after symptom onset, 921  
RA, effectiveness of Rehabilitation Activities Profile for structuring multidisciplinary care, 240  
validity of gout diagnoses in administrative data, 103  
Demography  
arthritis prevalence and, 553  
SLE, association with early disease damage, 993  
SLE, in rheumatology subspecialty care utilization, 593  
total knee replacement disparities, 562  
Depression  
appearance and, in rheumatic diseases, 303  
FM, mindfulness meditation for, 77  
OA, predictors of, 415  
RA, Mindfulness-Based Stress Reduction for, 1134  
in SSc, 1089  
Dermatomyositis (DM). *See also* Juvenile dermatomyositis (juvenile DM)  
creatine supplements vs. exercise for, 694  
physical training effects on muscle fiber composition, 1303  
resistance training benefits for, 756  
Devic's syndrome, neuromyelitis optica IgG autoantibody testing for diagnosis in SLE, 347  
Diabetes, bilateral internal carotid artery stenosis in, 1098  
Diagnosis  
PMR, clinical outcomes and quality of life in first year, 803  
SpA, accuracy of codes in VA Medical Center databases, 648  
subclinical atherosclerosis in PsA, 1074  
Dietary supplements, creatine, for idiopathic inflammatory myopathies, 694  
Disability. *See also* Functional disability; Work disability  
appearance and psychological distress in rheumatic diseases, 303  
hip arthroplasty in adults and, 364

Disability. *See also* Functional disability; Work disability (*cont'd*)  
JIA, proxy-reported health-related quality of life, 35  
OA knee pain and mobility restrictions outside home, 1381  
questionnaire assessment of, 705  
racial/ethnic differences in ADLs in older adults, 1058  
resistance training for chronic PM or DM, 756  
SSc, validity of measuring instruments for quality of life, 94, 1339  
Disease activity. *See also* Disease progression; Minimal disease activity (MDA)  
AS flares and new-onset IBD in anti-TNF therapy, 639  
Behcet's disease, clinical course, Italian population-based study, 171  
RA, power Doppler ultrasonographic assessment of joint inflammation, predictive value of, 116  
resistance training for chronic PM or DM, 756  
Disease Activity Score in 28 Joints (DAS28)  
RA, anti-TNF $\alpha$  tolerance and effectiveness in elderly patients, 679  
RA, Mindfulness-Based Stress Reduction and, 1134  
RA in pregnancy, 716  
RA and PsA, 256  
TNF $\alpha$  polymorphisms and RA response to etanercept, 1426  
Disease classification, criteria for rheumatic diseases, 1112, 1119  
Disease damage  
gout, validation of radiographic index for, 1067  
SLE, SF-6D predicting in LUMINA data, 986  
SLE, sociodemographic associations with early damage, 993  
Disease progression  
hip OA, pain and total hip replacement incidence in elderly, 1368  
juvenile DM, muscle biopsy for predicting course of, 1183  
OA, knee, prognostic factors, 13  
OA, knee, recreational physical activities and, 6  
OA, radiologic, in siblings, 626  
RA, power Doppler ultrasonographic assessment of joint inflammation, 116  
Disease-modifying antirheumatic drugs (DMARDs)  
administrative claims-identified adverse affects of, 343  
herpes zoster risk in RA and, 1431  
RA, ACR quality of care criteria and, 707  
RA, septic arthritis development and, 1151  
RA, use in older patients, 928  
SpA, accuracy of ICD-9 codes and prescription of, in VA databases, 648  
DM. *See* Dermatomyositis (DM)  
Drug therapy  
administrative claims-identified adverse affects of TNF $\alpha$  antagonists and DMARDs, 343  
for ANCA-associated vasculitis, 1552  
heel enthesitis in SpA, effects of switching anti-TNF agents, 1572  
Drug utilization  
DMARD use in older adults with RA, 928  
RA, agreement between patient report and medical record review for, 234  
racial/ethnic disparities in NSAID risk awareness, patient/doctor communication, and medicating behavior, 1539

## E

Economics. *See* Cost assessment  
Education, medical  
improving training in pediatric rheumatology, 1340  
reforms in musculoskeletal medicine education, 1109  
videotapes for assessing medical students' joint examination skills, 869  
Elderly. *See* Older adults  
Employment. *See also* Work disability  
SLE, memory impairment impact on, 1453  
SLE, work dynamics in, 56  
work-related problems in inflammatory arthritis, 1269

Enabling Self-Management and Coping with Arthritic Knee Pain through Exercise (ESCAPE-knee pain)  
 clinical effectiveness of, 1211  
 economic evaluation of, 1220

Endothelium, dysfunction in PsA patients without clinically evident cardiovascular disease, 287

Environmental factors  
 cell markers, cytokines, and immune parameters in cement mason apprentices, 147  
 OA knee pain and mobility restrictions outside home, 1381

Epidemiology  
 arthritis-attributable work disability, prevalence and correlates, 355  
 Behcet's disease, Italian population-based study, 171  
 pediatric arthritis and other rheumatic conditions, prevalence and annual ambulatory care visits in US, 2001-2004, 1439  
 SLE incidence in UK, 1990-1999, 612  
 small-vessel and medium-vessel vasculitis, 1552  
 work-related repetitive stress injury and leisure-time physical activity, 495

Errata, 886

Etanercept  
 adalimumab vs., for heel enthesitis in SpA, 1572  
 adverse effects identified from administrative claims data, 343  
 AS flares and new-onset IBD incidence with, 639  
 RA, therapeutic efficacy following failure of infliximab, 448 for refractory PMR, 1514  
 TNF $\alpha$  polymorphisms and RA response to, 1426  
 tuberculosis risk and treatment with, 756

Ethnicity  
 cultural factors in vitamin D deficiency, 1107  
 differences in ADL disability in older adults with arthritis, 1058  
 health disparities in rheumatic disease and, 547, 1343  
 knee OA, EQ-5D vs. SF-6D in multiethnic Asian patients, 1043  
 racial/ethnic disparities in NSAID risk awareness and usage, 1539  
 SLE, association with early disease damage, 993  
 SLE, low BMD in African American women, 585  
 SLE, multiethnic cohort modeling ethnic disparities, 576  
 SSc, pulmonary disorders and, GENISOS study, 318  
 total knee replacement disparities, 562

European League Against Rheumatism (EULAR), classification criteria for rheumatic diseases, 1112

EuroQoL (EQ-5D)  
 knee OA, SF-6D vs., in multiethnic Asian patients, 1043  
 RA, HAQ relationship with, 963

Evidence-based medicine, barriers to acceptance in practice, 1116

Exercise  
 effects on RA symptoms, function, and disease outcomes, 943  
 energy expenditure from lifestyle activities in RA, vs. healthy controls, 672  
 for idiopathic inflammatory myopathies, creatine supplements vs., 694  
 in integrated rehabilitation program for knee pain, 1211, 1220  
 JIA, in adolescents, aerobic and anaerobic exercise capacity, 898  
 JIA, in children, aerobic and anaerobic exercise capacity, 891  
 JIA, perceived adherence to treatment and, 226  
 JIA, physical fitness and, 887  
 JIA, and physical function in children, 1202  
 JIA, reliability of exercise testing and functional activity questionnaires in, 1446  
 JIA, treatment adherence and short-term outcomes, 905  
 long-term effectiveness for hip/knee OA, 1245  
 OA, hydrotherapy vs. Tai Chi for, 407  
 OA, knee, physical activity and, 1, 6  
 physical activity effect on knee joint structures in adults, 1261  
 physical training effects on muscle fiber composition in PM and DM, 1303  
 resistance training for chronic PM or DM, 756

SLE, Siconolfi Step Test, 1007  
 work-related repetitive stress injury and leisure-time physical activity, 495

## F

Factor analysis, dyadic efficacy of married women with RA and their spouses, 294

Family  
 mothers with inflammatory arthritis, 381  
 radiologic OA disease progression in siblings, 626

Fatigue  
 measurement scales for RA, 429  
 measurement in SLE, 1348

Fatigue Severity Scale (FSS), 1348

Fee-for-service  
 health services utilization in SLE, HMO vs., 508

Fibromyalgia (FM)  
 absence of synovitis in joint pain in Gulf War veterans' illness, 1316  
 insurance coverage and patient use of complementary and alternative medicine, 71

juvenile, social functioning and peer relationships in adolescents, 474  
 mindfulness meditation for depression, 77  
 operant and cognitive-behavioral therapy for, 830

Fingers, tenosynovitis in untreated early RA, ultrasound vs. MRI, 1158

Focus groups, for OA joint pain assessment, 666

Fragility fractures, osteoporosis and management of, 1502

Framingham Offspring Study, knee OA, physical activity and, 1, 6

Functional Assessment of Chronic Illness Therapy Fatigue Scale, in RA, 429

Functional disability  
 in adults with hip arthroplasty, longitudinal study, 364  
 hand OA, self-report instruments vs. hand function tests for assessing, 1230  
 JIA, JAQS vs. C-HAQ for measuring, 913  
 knee OA, poor proprioception and muscle strength in, 787  
 OA, long-term outcome of total hip replacement, 1375  
 RA, accommodations for life activities and, 730

Functional Index of Hand OA (FIHOA), 1230

## G

Gait. See also Walking  
 knee OA, anatomic realignment and muscle function during, 389  
 knee OA, medial, knee movement strategies in, 1018  
 knee OA, test-retest reliability of peak knee adduction moment in, 1012

Gastrointestinal diseases  
 SSc, development of gastrointestinal health-related quality of life instrument, 1280  
 ulceration in juvenile DM, 881

Gastroprotection, celecoxib with proton-pump inhibitors vs. NSAIDs, in elderly patients, 748

GC. See Glucocorticoids (GC)

Gender. See also Women  
 internal carotid artery stenosis in diabetic male, 1098  
 sexual biology and age distribution in SLE, 608  
 total hip replacement outcomes, obesity and, 327

Genetics  
 hereditary multiple exostosis with JIA and brachydactyly, 1568  
 OA, radiologic disease progression in siblings, 626  
 RA, HLA-DRB1 and inflammation in cardiovascular mortality, 125  
 RA response to etanercept, TNF $\alpha$  polymorphisms and, 1426  
 Raynaud's phenomenon, cold response in twins, 524  
 Schmorl's nodes and lumbar disc disease, 855

Genetics, Arthrosis and Progression (GARP) study, 626

Genetics versus Environment in Scleroderma Outcome Study (GENISOS), 318

Giant cell arteritis (GCA), atherosclerosis in, 1481

Glucocorticoids (GC)  
 cardiovascular events in rheumatic diseases and, 191  
 cardiovascular risk in PMR and use of, 279  
 with cyclophosphamide, for Churg-Strauss syndrome, 686  
 osteoporosis caused by, barriers in management of, 140

- Glucocorticoids (GC) (cont'd)**
- PMR activity score for predicting dose changes, 481
  - Gonadal hormones, in SLE, 608
  - Gout**
    - coffee consumption and serum uric acid levels, 816
    - CT vs. physical measurement of tophus volume, 461
    - metabolic syndrome in, 109
    - optimal serum uric acid levels in, therapeutic target, 1324
    - quality of care indicators, 822
    - radiographic damage index, validation of, 1067
    - validity of diagnoses in administrative data, 103
  - Grip strength, for hand OA functional assessment, 1230
  - Grounded theory, and mothers with inflammatory arthritis, 381
  - Gulf War veterans' illness, absence of synovitis in joint pain, 1316
- H**
- Habitual Activity Estimation Scale (HAES), in children with JIA, 1446
- Hand**
- AUSCAN Hand Index, reliability and validity in older adults, 423
  - OA, self-report instruments vs. hand function test for functional assessment, 1230
  - OA vs. RA, and health-related quality of life, 1404
- Health Assessment Questionnaire (HAQ)
- arthritis patient participation in self-management programs, 851
  - construct validity in SSc, 94, 1339
  - disability index vs. SF-36 physical functioning subscale for PsA and RA, 723
  - OA, for hand function measurement, 1230
  - RA, accommodations for life activities and disability scores, 730
  - RA, for estimating preference-based single indices in, 963
  - RA in pregnancy, 716
  - RA, tolerance and effectiveness of anti-TNF $\alpha$  therapy in elderly patients, 679
- Health behavior, low back and neck pain correlates in adults, 656
- Health care costs. See Cost assessment; Cost effectiveness
- Health disparities
- arthritis prevalence, 553
  - arthritis self-management education reducing, 1081
  - racial/ethnic disparities in NSAID risk awareness, patient/doctor communication, and medicating behavior, 1539
  - in rheumatic disease, 547, 1343
  - SLE, low BMD in African American women, 585
  - SLE, Medicaid and access to care, 601
  - SLE, multiethnic cohort modeling, 576
  - SLE, socioeconomic/demographic factors in rheumatology care utilization, 593
  - total knee replacement, 562
  - total knee replacement, racial, decision aid for reducing, 568
- Health insurance
- administrative claims-identified adverse effects of TNF $\alpha$  antagonists and DMARDs, 343
  - FM, coverage and use of complementary and alternative medicine providers, 71
  - HMO vs. fee-for-service and health services utilization, 508
  - Medicaid and access to SLE care, 601
- Health maintenance organization (HMO)
- SLE, health services utilization, vs. fee-for-service, 508
  - validity of gout diagnoses in administrative data, 103
- Health-related quality of life
- AS, adalimumab effects on, 1050
  - hand OA vs. hand RA, 1404
  - JIA, proxy-reported, 35
  - juvenile SLE, validation of SMILEY measure for, 1165
  - knee OA, EQ-5D vs. SF-6D in multiethnic Asian patients, 1043
  - SLE, LopusQoL measure for adults, development and validation, 972
  - SLE, SF-6D predicting damage accrual and mortality in, 986
  - SSc, development of gastrointestinal health-related quality of life instrument for, 1280
- Health services utilization**
- early aggressive care and delayed recovery from whiplash injury, 861
  - FM, insurance coverage and use of complementary and alternative medicine providers, 71
  - new-onset RA, delay in consultation with specialist, 1419
  - OA, case management in primary care, 1390
  - pediatric arthritis and other rheumatic conditions, annual ambulatory care visits in US, 2001-2004, 1439
  - SLE, HMO vs. fee-for-service, 508
  - SLE, socioeconomic/demographic factors in rheumatology care utilization, 593
  - total knee replacement, decision aid for reducing racial disparities, 568
  - total knee replacement, disparities in, 562
- Health status**
- age, sex and obesity in arthritis, 553
  - AS, Patient Acceptable Symptom State for, 133
  - RA, HAQ relationship to preference-based single indices, 963
  - RA, PDA vs. paper-pencil format for patient diary, 454
  - SLE, SF-6D as measure for, 986
  - SSc, health values of patients, 86
- Health values**
- OA, patient beliefs about causes of, 267
  - SLE, coverage of concepts important to patients by measures of disease activity and health status, 1287
  - SSc, health values of patients, 86
- Heel enthesitis, in SpA, effects of switching TNF $\alpha$  inhibitors for, 1572
- Henoch-Schönlein purpura, malignancies associated with, 1473
- Hepatitis C virus, B cell lymphoma and infection in SS, 161
- Herbal medicine, *Ganoderma lucidum* and San Miao San for RA, 1143
- Hereditary multiple exostosis, with coexistent JIA and short digits, 1568
- Herpes zoster, DMARDs and risk in RA, 1431
- Hip**
- OA, long-term effectiveness of exercise therapy for, 1245
  - OA pain, disease progression and total hip replacement in elderly, 1368
  - OA, short vs. long form WOMAC function scale for, 633
- Hip Disability and Osteoarthritis Outcome Score, pain assessment in OA focus groups, 666
- Hip replacement
- disability evolution, longitudinal study, 364
  - in nonagenarians and centenarians, 1038
  - total, incidence, pain, and OA progression in elderly, 1368
  - total, long-term outcome in OA, 1375
  - total, obesity and gender in outcomes of, 327
  - total, patient avoidance of, 27
- Hispanics, pulmonary disorders in SSc, GENISOS study, 318
- HLA-DRB1, and cardiovascular mortality and inflammation in RA, 125
- Human papillomavirus (HPV), infection risk and cervical squamous intraepithelial lesions in SLE, 619
- Hyaluronic acid
- hylian vs., for knee OA, 1410
  - prognostic factors for knee OA progression, 13
- Hydrocephalus, in neonatal lupus erythematosus, 261
- Hydrotherapy, Tai Chi vs., for OA, 407
- Hylian, vs. hyaluronic acid for knee OA, 1410
- Hypertension, cognitive impairment in SLE and, 1461
- Hypomagnesemia, in chondrocalcinosis, 1496
- I**
- IgG autoantibodies, for Devic's syndrome diagnosis in SLE, 347
- Imaging. See also specific imaging techniques
- finger tenosynovitis in untreated early RA, ultrasound vs. MRI, 1158
  - relationship between clinical and imaging remission of RA following anti-TNF therapy, 1564
- Immune response, silica exposure in cement mason apprentices, 147

- Indirect costs. *See* Cost assessment  
 Indomethacin, vs. COX-2 inhibitors in congestive heart failure risk, 516  
 Infection opportunistic, administrative claims-identified, associated with TNF $\alpha$  antagonists and DMARDs, 343  
 total hip replacement and, obesity and gender in, 327  
 Inflammation HLA-DRB1 and cardiovascular mortality in RA, 125  
 power Doppler ultrasonographic assessment in RA, predictive value, 116  
 Inflammatory arthritis mothers with, 381  
 occupational stress measurement, 738  
 reduced incidence of orthopedic surgery in Norway for, 529  
 work-related problems in, 1269  
 Inflammatory bowel disease (IBD), AS flares and new-onset incidence with anti-TNF $\alpha$  agents, 639  
 Inflammatory pseudotumor of liver, in RA, 1102  
 Infliximab adverse effects identified from administrative claims data, 343  
 AS flares and new-onset IBD incidence with, 639  
 RA, etanercept therapeutic efficacy following therapeutic failure with, 448  
 tuberculosis risk and treatment with, 756  
 Informed decision making, decision aid for total knee replacement, 568  
 Insurance. *See* Health insurance  
 Interleukin-18 (IL-18), in adult-onset Still's disease, 1530  
 International Classification of Diseases, Ninth Revision (ICD-9), accuracy of SpA codes in VA databases, 648  
 International Classification of Functioning, Disability and Health (ICF)  
 knee pain and mobility restrictions outside home, 1381  
 PsA, self-report instruments assessing functioning, patient perspectives on, 487  
 RA, patient satisfaction in multidisciplinary team care, 240  
 International League of Associations for Rheumatology (ILAR), global health initiatives, 885  
 International normalized ratio, anticoagulation dosage in APS, 1346  
 Interobserver agreement, patient report and medical record review for RA medications used, 234  
 Interpersonal relations, dyadic efficacy of married women with RA and their spouses, 294  
 Intervertebral disc disease, Schmorl's nodes and, 855  
 Italian population, Behcet's disease epidemiology and clinical course, 171  
 Item-response theory, SF-36 physical functioning subscale vs. HAQ disability index for PsA and RA, 723
- J**
- Jebsen-Taylor Hand Function Test, for OA, 1230  
 Joint(s)  
 focus group assessment of chronic pain, 666  
 knee OA, muscle strength and knee movement in walking, 1018  
 RA, development and validation of Joint Protection Behavior Assessment, German version, 249  
 RA, power Doppler ultrasonographic assessment of inflammation, predictive value, 116  
 Joint hypermobility syndrome, musculoskeletal reflex in, 1329  
 Joint loading  
 knee OA, pain and medial joint loading, 1254  
 knee OA, test-retest reliability of peak knee adduction moment during walking, 1012  
 Joint replacement. *See also* Hip replacement; Knee replacement  
 reduced use for inflammatory arthritis in Norway, 529  
 Joint space narrowing, radiologic OA progression in siblings, 626  
 Juvenile Arthritis Functionality Scale (JAFS), development and validation for JIA, 913  
 Juvenile dermatomyositis (juvenile DM)  
 gastrointestinal pain and ulceration in, 881
- K**
- Juvenile dermatomyositis (juvenile DM) (*cont'd*)  
 international consensus on scoring system for muscle biopsy evaluation, 1192  
 muscle biopsy for predicting course of disease, 1183  
 Juvenile fibromyalgia (juvenile FM), social functioning and peer relationships in adolescents, 474  
 Juvenile idiopathic arthritis (JIA)  
 aerobic and anaerobic exercise capacity in adolescents, 898  
 caregiver recall of treatment recommendations, 219  
 delayed access to care after musculoskeletal symptom onset, 921  
 economic impact of, 44  
 exercise in, 887  
 exercise capacity in children, 891  
 exercise and physical function in children, 1202  
 health-related quality of life in, 35  
 hereditary multiple exostosis with brachydactyly and, 1568  
 perceived adherence to treatment, 226  
 reliability of exercise testing and functional activity questionnaires, 1446  
 streptococcal infection in flares, 877  
 TMJ ultrasonography in, 213  
 treatment adherence and short-term outcomes, 905  
 validation of JAFS scale for physical function measurement, 913  
 Juvenile systemic lupus erythematosus (juvenile SLE)  
 neonatal, hydrocephalus and macrocephaly in, 261  
 pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) validation in childhood-onset SLE, 1174  
 validation of pediatric health-related quality of life measure, 1165  
 Juvenile systemic sclerosis (juvenile SSC), provisional classification criteria for, 203
- K**
- Knee  
 OA, anatomic realignment and muscle function during gait, 389  
 OA, EQ-5D vs. SF-6D in multiethnic Asian patients, 1043  
 OA, exercise therapy, long-term effectiveness, 1245  
 OA, hyaluronic acid for, 1410  
 OA, medial, knee movement strategies in walking, 1018  
 OA, medial, test-retest reliability of peak knee adduction moment during walking, 1012  
 OA, Oxford Knee Scale construct validity, 1363  
 OA, pharmacist screening and referral of undiagnosed disease, 1238  
 OA, physical activity and, 1  
 OA, poor proprioception causing muscle weakness and functional disability, 787  
 OA, prognostic factors of progression, 13  
 OA, proprioception measurement reproducibility, 1398  
 OA, radiographic, probability in older adults, 794  
 OA, recreational physical activities and development of, 6  
 OA, short vs. long form WOMAC function scale for, 633  
 OA, varus-valgus alignment, MRI vs. radiographic assessment, 398  
 patella cartilage volume/defects and bone defects in women, 272  
 physical activity effect on joint structures in adults, 1261  
 Knee Injury and Osteoarthritis Outcome Score, 666  
 Knee pain  
 integrated rehabilitation using exercise, self-management, and coping strategies, 1211, 1220  
 OA, medial knee joint loading and, 1254  
 OA, and mobility restrictions outside home, 1381  
 OA, probability in older adults, 794  
 Knee replacement  
 in nonagenarians and centenarians, 1038  
 total, decision aid for reducing racial disparities in, 568  
 total, health disparities in, 562, 1342  
 total, patient avoidance of, 27

## L

- Leukocytes, peripheral blood, apoptosis and IL-18 in adult-onset Still's disease, 1530  
Leukoencephalopathy, progressive multifocal, differential diagnosis in SLE, 352  
Leukotriene inhibitors, Churg-Strauss syndrome and, 1552  
Lifestyle  
  energy expenditure from lifestyle physical activities in RA, vs. healthy controls, 672  
  OA, knee, recreational physical activities and development of, 6  
Liver, inflammatory pseudotumor in RA, 1102  
Low back pain. *See* Back pain  
Lumbar disc disease, Schmorl's nodes and, 855  
Lupus. *See* Systemic lupus erythematosus (SLE)  
Lupus anticoagulant, as marker in cutaneous polyarteritis nodosa, 1707  
Lupus in Minorities, NAture versus nurture study (LUMINA)  
  SLE, multiethnic cohort modeling ethnic disparities, 576  
  SLE, SF-6D predicting damage accrual and mortality, 986  
LupusQoL, development and validation for adults, 972  
Lymphoma, B cell, with hepatitis C infection, in SS, 161

## M

- Macrocephaly, in neonatal lupus erythematosus, 261  
Magnesium depletion, in chondrocalcinosis, 1496  
Magnetic resonance imaging (MRI)  
  AS, validation of SPARCC spinal inflammation index for, 501  
  high-sensitivity CRP in chronic low back pain with vertebral end-plate signal changes, 1311  
  lesions and cognitive impairment in SLE, 1461  
  OA of knee, assessment of varus-valgus alignment, radiography vs., 398  
  physical activity effect on knee joint structures in adults, 1261  
  ultrasound vs., for diagnosing finger tenosynovitis in untreated early RA, 1158  
Magnetic resonance spectroscopy,  $^{31}\text{P}$ , for muscle function assessment, 694  
Malignancies, vasculitis characteristics and outcomes associated with, 1473  
Malignant hyperthermia, statin-induced adverse effects and susceptibility to, 186  
Marriage, dyadic efficacy of women with RA and their spouses, 294  
MDA. *See* Minimal disease activity (MDA)  
Measuring instruments. *See also* Questionnaires; Short Form 36 (SF-36)  
  AS, SPARCC MRI spinal inflammation index, 501  
  AUSCAN Hand Index, 423, 1230  
  Chronic Illness Job Strain Scale (CIJSS), 738  
  classification criteria for rheumatic diseases, 1119  
  hand OA, self-report instruments vs. hand function tests for functional assessment, 1230  
  JIA, Childhood Health Assessment Questionnaire, 35, 913, 1446  
  JIA, JAFS, 913  
  JIA, reliability of exercise testing and functional activity questionnaires, 1446  
  juvenile DM, international consensus on scoring system for muscle biopsy evaluation, 1192  
  juvenile SLE, Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY), 1165  
  knee OA, EQ-5D vs. SF-6D in multiethnic Asian patients scheduled for knee replacement, 1043  
  OA, Oxford Knee Scale, Rasch analysis of construct validity, 1363  
  Paffenbarger Physical Activity and Exercise Index, 672  
  pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM) validation in childhood-onset SLE, 1174  
  PMR-AS, 481, 810  
  PsA, self-report instruments, 487  
  RA, DAS28 in pregnancy, 716  
  RA, fatigue measurement scales, 429  
  RA, ICF, 240  
  RA, Joint Protection Behavior Assessment, German version, 249  
Measuring instruments. *See also* Questionnaires; Short Form 36 (SF-36) (*cont'd*)  
  RA and PsA, DAS28 for, 256  
  RA, Rehabilitation Activities Profile (RAP), 240  
  SLE, coverage of concepts important to patients by standard measures of disease activity and health status, 1287  
  SLE, fatigue measures, 1348  
  SLE, LupusQoL for adults, 972  
  SLE, Medication Adherence Self-Report Inventory, 1000  
  SSC, Cochin Hand Function Scale (CHFS), 94  
  SSC, disability and quality of life, validity of measuring instruments, 94, 1339  
  SSC, HAQ, 94, 1339  
  Vasculitis Self-Management Scale, for ANCA-associated vasculitis, 1296  
  WOMAC function scale, short vs. long form in hip and knee OA, 633  
Medicaid, access to SLE care and, 601  
Medical education. *See* Education, medical  
Medical Outcomes Study 36-Item Short Form Health Survey. *See* Short Form 36 (SF-36)  
Medical records, RA, agreement between patient report and medical record review for medications used, 234  
Medicare  
  DMARD use in older adults with RA, 928  
  G-code measures for quality of care, 703  
Medication Adherence Self-Report Inventory (MASRI), for SLE, 1000  
Meditation  
  mindfulness meditation for depression in FM, 77  
  in Mindfulness-Based Stress Reduction for RA, 1134  
Memory impairment, impact on employment status in SLE, 1453  
Metabolic syndrome, prevalence in gout, 109  
Mindfulness-Based Stress Reduction  
  for depression in FM, 77  
  effects in RA, 1134  
Minimal disease activity (MDA)  
  RA, long-term outcomes and, 935  
  RA, preliminary definitions, evaluation of, 440  
Moberg Picking-Up Test (MPUT), 1230  
Mobility, knee pain and restrictions outside home, 1381  
Mortality  
  cardiovascular, HLA-DRB1-related inflammation in RA and, 125  
  knee and hip arthroplasty in nonagenarians and centenarians, 1038  
  SLE, SF-6D predicting from LUMINA data, 986  
MRI. *See* Magnetic resonance imaging (MRI)  
Multidimensional Assessment of Fatigue (MAF), in RA, 429  
Multidisciplinary team care, Rehabilitation Activities Profile for structuring in RA, 240  
Muscle strength  
  creatine supplements vs. exercise for idiopathic inflammatory myopathies, 694  
  knee OA, quadriceps strength, knee laxity and instability affecting knee movement, 1018  
  poor proprioception and functional disability in knee OA, 787  
Muscles  
  biopsy, international consensus on scoring system for muscle biopsy in juvenile DM, 1192  
  biopsy, for predicting course of juvenile DM, 1183  
  knee OA, osteotomy and muscle function during gait, 389  
  physical training effects on muscle fiber composition in PM and DM, 1303  
Musculoskeletal disorders  
  educational reform, 1109  
  reflex function in joint hypermobility syndrome, 1329  
  work disability interventions, time course and effectiveness of, 335  
Mutations, hereditary multiple exostosis with JIA and brachydactyly, 1568

## N

- National Ambulatory Medical Care Survey, 1439  
National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III), 109  
National Health and Nutrition Examination Survey, Third (NHANES-III)  
antioxidant and cardiovascular risk factors in RA, 953  
metabolic syndrome in gout, 109  
serum uric acid levels and caffeine consumption, 816  
National Health Information Survey, 355  
National Hospital Ambulatory Medical Care Survey, 1439  
Neck pain, prevalence and correlates with low back pain in adults, 656  
Neonatal lupus erythematosus, hydrocephalus and macrocephaly in, 261  
Neuromuscular biopsy, in SS-related peripheral neuropathy, 1520  
Neuromyelitis optica, IgG autoantibody testing, for Devic's syndrome, 347  
Nonsteroidal antiinflammatory drugs (NSAIDs)  
  celecoxib with proton-pump inhibitors vs., gastroprotection in elderly patients, 748  
  congestive heart failure risk, vs. COX-2 inhibitors, 516  
  racial/ethnic disparities in risk awareness and behavior, 1539  
Norway, reduced use of orthopedic surgery for inflammatory arthritis, 529

## O

- OA. See Osteoarthritis (OA)  
Obesity  
  arthritis prevalence and, 553  
  total hip replacement outcomes, gender and, 327  
Objective structured clinical examination, videotaped, for assessing medical students' joint examination skills, 869  
Occupational disorders. See Work disability  
Occupational therapy, development and validation of Joint Protection Behavior Assessment, German version (D-JPBA-S), 249  
Older adults. See also Aging  
  AUSCAN Hand Index, reliability and validity in, 423  
  celecoxib with proton-pump inhibitors vs. NSAIDs, gastrointestinal safety in, 748  
  DMARD use in RA, 928  
  hip OA pain and disease progression and total hip replacement in, 1368  
  knee and hip arthroplasty in nonagenarians and centenarians, 1038  
  knee OA, radiographic, estimating probability, 794  
  RA, tolerance and effectiveness of anti-TNF $\alpha$  therapy in, 679  
  racial/ethnic differences in ADL disability in arthritis, 1058  
Oligoarthritis, corticosteroids followed by sulfasalazine vs. conservative treatment for, 154  
Operant-behavioral therapy predictors for FM outcome, 830  
Opportunistic infections, associated with TNF $\alpha$  antagonists and DMARDs, 343  
Organ systems, in provisional classification criteria for juvenile SSc, 203  
Orthopedic surgery, reduced use for inflammatory arthritis in Norway, 529  
Osteoarthritis (OA)  
  AUSCAN Hand Index, reliability and validity in older adults, 423  
  familial factors in radiologic disease progression in siblings, 626  
  hand, health-related quality of life, OA vs. RA, 1404  
  hand, self-report instruments vs. hand function tests for functional assessment, 1230  
  hip, disease progression and total hip replacement in elderly, 1368  
  hip and knee, long-term effectiveness of exercise therapy, 1245  
  hip and knee, patient avoidance of total joint arthroplasty, 27  
  hip and knee, WOMAC short form validation for, 633  
  hydrotherapy vs. Tai Chi for managing, 407  
  joint pain assessment in focus groups, 666
- Osteoarthritis (OA) (cont'd)  
  knee, anatomic realignment and muscle function during gait, 389  
  knee, construct validity of Oxford Knee Scale, 1363  
  knee, EQ-5D vs. SF-6D in multiethnic Asian patients, 1043  
  knee, hyaluronic acid for, 1410  
  knee, movement strategies in walking, 1018  
  knee, pain and medial joint loading in, 1254  
  knee, pharmacist screening and referral of undiagnosed disease, 1238  
  knee, physical activities and, 1, 6  
  knee, prognostic factors of progression, 13  
  knee, proprioception, muscle strength, and functional ability in, 787  
  knee, radiographic, probability in older adults, 794  
  knee, radiographic vs. MRI assessment of varus-valgus alignment, 398  
  knee, test-retest reliability of peak knee adduction moment during walking, 1012  
  occupational stress measurement, 738  
  patellofemoral, factors affecting patella cartilage volume and defects and bone volume in women, 272  
  patient beliefs about causes of, 267  
  patient participation in self-management programs, 851  
  predictors of depression in, 415  
  reproducibility of knee joint proprioception measurement, 1398  
  self-management education and primary care case management, controlled trial, 1390  
  total hip replacement, long-term outcome, 1375  
Osteoporosis  
  fragility fracture management and, 1502  
  GC-induced, barriers in management of, 140  
Osteotomy, knee OA, anatomic realignment and muscle function during gait, 389  
Outcome Measures in Rheumatology (OMERACT)  
  contributions to rheumatic disease research, 186  
  RA, MDA and remission, preliminary definitions, 440  
  RA, PDA vs. paper-pencil format for patient diaries, 454  
Outcomes  
  AS, adalimumab effects on health-related quality of life, 1050  
  CARE IV conference report, 1334  
  dyadic efficacy of married women with RA and their spouses, 294  
  exercise therapy for hip/knee OA, long-term effectiveness, 1245  
  FM, behavioral therapy predictors of, 830  
  gout, radiographic damage index validation, 1067  
  JIA, JAQS vs. C-HAQ for physical function measurement, 913  
  JIA, reliability of exercise testing and functional activity questionnaires in, 1446  
  JIA, short-term outcomes and treatment adherence, 905  
  knee and hip arthroplasty in nonagenarians and centenarians, 1038  
  long-term, for OA total hip replacement, 1375  
  low back pain, brief pain management program vs. physical therapy and, 466  
  OA, case management in primary care, controlled trial, 1390  
  oligoarthritis, intraarticular corticosteroids followed by sulfasalazine vs. conservative treatment for, 154  
  pediatric WG, clinical features and, 837  
  PMR, quality of life and diagnostic uncertainty in first year, 803  
  RA, etanercept therapeutic efficacy following failure of infliximab, 448  
  RA, exercise effects on, 943  
  RA, minimal disease activity or remission and, 935  
  Rasch measurement model in rheumatology, 1358  
  small-vessel and medium-vessel vasculitis, 1552  
  SSc, disability and quality of life, validity of measuring instruments, 94, 1339  
  SS-related peripheral neuropathy, neuromuscular biopsy and, 1520  
  total hip replacement, obesity and gender in, 327  
  vasculitis associated with malignancies, 1473  
  whiplash injuries, early aggressive care and delayed recovery from, 861

Oxford Knee Scale, OA, Rasch analysis of construct validity, 1363  
Oxygen uptake, maximal  
in adolescents with JIA, 898  
Siconolfi Step Test in SLE, 1007

## P

Pain. *See also* Back pain; Knee pain  
absence of synovitis in joint pain in Gulf War veterans' illness, 1316  
chronic joint pain assessment in focus groups, 666  
neck pain, correlation with low back pain in adults, 656  
Parent Adherence Report Questionnaire (PARQ)  
JIA, caregiver recall of treatment recommendations, 219  
JIA, perceived adherence to treatment, 226  
Parenteral nutrition, chondrocalcinosis and magnesium depletion in, 1496  
Parenting, mothers with inflammatory arthritis, 381  
Patient Acceptable Symptom State (PASS), evaluation and validation for AS, 133  
Patient Activity Scale (PAS), minimal disease activity and remission in RA, 935  
Patient diaries, PDA vs. paper-pencil format for, 454  
Patient-doctor relationship, racial/ethnic disparities in NSAID risk awareness and, 1539  
Patient education  
decision aid for reducing racial discrepancies in total knee replacement, 568  
self-management education for arthritis, 1081  
Patient Health Questionnaire (PHQ-9), depression predictors in OA, 415  
Patient registries, agreement between RA patient report and medical record review for medications used, 234  
Patient satisfaction, Rehabilitation Activities Profile for structuring RA multidisciplinary team care, 240  
Patients  
avoidance of total joint replacement for OA of hip or knee, 27  
beliefs about causes of OA, 267  
participation in arthritis self-management programs, 851  
participation in atherosclerosis prevention trials in SLE, factors determining, 49  
PsA, perspectives on self-report instruments assessing functioning, 487  
SLE, coverage of concepts important to patients by standard measures of disease activity and health status, 1287  
Pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM), validation in childhood-onset SLE, 1174  
Pediatric rheumatology. *See* Children; Juvenile  
Peer relations, in adolescent FM, 474  
Peripheral blood mononuclear cells, leukocyte apoptosis and IL-18 in adult-onset Still's disease, 1530  
Personal digital assistant (PDA), for RA patient diary, 454  
Pharmacists, screening and referral of undiagnosed knee OA, 1238  
Physical activity. *See also* Exercise  
Physical fitness  
exercise and physical function in children with JIA, 1202  
JIA, exercise and, 887  
JIA, exercise capacity in children, 891  
Siconolfi Step Test for SLE assessment, 1007  
Physical therapy. *See also* Exercise  
brief pain management program vs., for low back pain, 466  
following joint distension for adhesive capsulitis, efficacy and cost-effectiveness, 1027  
Physician adherence. *See* Delivery of health care  
PM. *See* Polymyositis (PM)  
PMR. *See* Polymyalgia rheumatica (PMR)  
Polyangiitis, microscopic, malignancies associated with, 1473  
Polyarteritis nodosa  
cutaneous, aPL in, 1507  
malignancies associated with, 1473  
Polymorphisms, TNF $\alpha$ , and RA response to etanercept, 1426

Polymyalgia rheumatica (PMR)  
clinical outcomes, quality of life and diagnostic uncertainty in, 803  
GC-related cardiovascular risk in, 279  
PMR-AS validity and proposed definition of remission, 810  
refractory, etanercept for, 1514  
Polymyalgia Rheumatica Activity Score (PMR-AS)  
predicting GC dose changes with, 481  
validity and proposed remission threshold, 810  
Polymyositis (PM)  
creatine supplements vs. exercise for, 694  
physical training effects on muscle fiber composition in, 1303  
resistance training benefits for, 756  
Predictors  
depression in OA, 415  
juvenile DM, muscle biopsy predicting course of, 1183  
knee OA, radiographic, in older adults, 794  
new-onset RA, delay in consultation with specialist, 1419  
OA, knee, prognostic factors for progression, 13  
RA, power Doppler ultrasonographic assessment of joint inflammation, 116  
subclinical atherosclerosis in PsA, 1074  
Prednisolone, etanercept and reduced steroid dosage for refractory PMR, 1514  
Prednisone, causing osteoporosis, barriers in management, 140  
Pregnancy  
RA activity measures in, 716  
in SLE, 608  
Productivity  
cumulative indirect costs of SLE in US, Canada, and UK, 64  
employment and SLE, 56  
Profile of Mood States, for fatigue measurement in RA, 429  
Progressive multifocal leukoencephalopathy, in SLE, differential diagnosis, 352  
Proprioception  
knee OA, dysfunction affecting muscle strength and functional ability, 787  
knee OA, reproducibility of measurement in knee joint, 1398  
Proton-pump inhibitors, celecoxib vs. NSAIDs with, for gastroprotection in elderly, 748  
Psoriatic arthritis (PsA)  
DAS28 for, 256  
endothelial dysfunction in patients without clinically evident cardiovascular disease, 287  
self-report instruments for, patient perspectives on, 487  
sensitivity of CASPAR criteria, 1560  
SF-36 physical functioning subscale vs. HAQ disability index for assessing, 723  
subclinical atherosclerosis prevalence in, 1074  
Psychological disorders  
low back and neck pain correlates in adults, 656  
RA, Mindfulness-Based Stress Reduction for, 1134  
SLE, appearance and psychological distress in, 303  
Psychometrics  
knee OA, Rasch analysis of Oxford Knee Scale construct validity, 1363  
Rasch analysis for outcomes measurement, 1358  
Psychosocial factors, in evidence-based medicine, 1116  
Pulmonary disorders, in SSc, GENISOS study, 318

## Q

Qualitative research  
patient avoidance of total joint replacement for OA of hip or knee, 27  
SLE, factors determining participation in atherosclerosis preventive trials in, 49  
Quality-adjusted life years (QALYs)  
brief pain management program vs. physical therapy for low back pain, 466  
HAQ relationship to preference-based single indices in RA, 963  
Quality of care  
ACR criteria for RA, 707  
DMARD use in older adults with RA, 928

**Quality of care (cont'd)**  
indicators for, 703  
indicators for gout, 822  
**Quality of life.** See also *Health-related quality of life*  
AS, Patient Acceptable Symptom State and, 133  
JIA, treatment adherence and short-term outcomes in children, 905  
OA, long-term outcome of total hip replacement, 1375  
OA, self-management education in primary care case management, 1390  
PMR, clinical outcome and diagnostic uncertainty in first year, 803  
SLEQOL cross-cultural adaptation into Chinese, 980  
SSc HAQ, disability and, validity of measuring instruments, 94, 1339  
SSc, health values of patients and, 86  
**Questionnaires**  
AS, Patient Acceptable Symptom State, 133  
community pharmacist screening for knee OA, 1238  
effective use in clinical practice, 705  
JIA, health-related quality of life, 35  
JIA, JAFS vs. C-HAQ for physical function measurement, 913  
JIA, Parent Adherence Report Questionnaire, 219, 226  
JIA, reliability of exercise testing and functional activity questionnaires, 1446  
rheumatology subspecialty choice, factors in, 1546  
SLEQOL cross-cultural adaptation into Chinese, 980  
SSc, development of gastrointestinal health-related quality of life instrument, 1280

## R

RA. See *Rheumatoid arthritis (RA)*  
Race. See *Ethnicity*  
**Radiography**  
damage index for gout, validation of, 1067  
knee OA, assessment of varus-valgus alignment, MRI vs., 398  
knee OA, estimating probability in older adults, 794  
OA disease progression in siblings, 626  
**Rasch analysis**  
construct validity of Oxford Knee Scale, 1363  
in rheumatology outcomes measurement, 1358  
**Raynaud's phenomenon**  
cognitive impairment in SLE and, 1461  
heritability and cold response in twins, 524  
**Recovery**, delayed, early aggressive care for whiplash injuries and, 861  
**Referral**, JIA diagnosis and delays in pediatric rheumatology assessment, 921  
**Reflexes**, musculoskeletal, in joint hypermobility syndrome, 1329  
**Rehabilitation Activities Profile (RAPS)**, effectiveness in structuring multidisciplinary RA team care, 240  
**Rehabilitation**, knee pain, integrated program using exercise, self-management, and coping strategies, 1211, 1220  
**Relationships**, FM in adolescents, social functioning and peer relationships, 474  
**Remission**  
PMR, proposed definition for, 810  
RA, absence of imaging synovitis vs. low level of disease as, 1564  
RA, MDA and long-term outcomes, 935  
RA, preliminary definitions, evaluation of, 440  
**Repetitive stress injury**, leisure-time physical activity and, 495  
**Reproducibility of results**  
knee joint proprioception measurement in OA, 1398  
reliability of exercise testing and functional activity questionnaires in JIA, 1446  
**Research**  
classification criteria for rheumatic diseases and, 1119  
recruitment of participants for, 3  
rheumatic disease, OMERACT contributions to, 186  
SLE, patient recruitment for clinical trials in, 49  
**Response to treatment**  
RA, hybrid ACR criteria for, 189

**Response to treatment (cont'd)**  
RA, proposed revision to ACR20, 193  
TNF $\alpha$  polymorphisms and RA response to etanercept, 1426  
Retinopathy, Purtzscher-like, in adult-onset Still's disease with thrombotic thrombocytopenic purpura, 182  
Revised Activity Scale for Kids (ASK), reliability in JIA, 1446  
Rheoyme, whole blood viscosity and arterial thrombosis in SLE, 845  
**Rheumatoid arthritis (RA)**  
accommodations for valued life activities, 730  
ACR quality criteria assessment, 707  
antioxidants and cardiovascular risk factors in, 953  
anti-TNF therapy for, relationship between clinical and imaging remission, 1564  
appearance and psychological distress in, 303  
Chinese herbal remedies for, 1143  
DAS28 for, 256  
disease activity measures in pregnancy, 716  
DMARD use in older adults, 928  
DMARDs and septic arthritis in, 1151  
dyadic efficacy of married women and their spouses in, 294  
energy expenditure from lifestyle activities, vs. healthy controls, 672  
etanercept efficacy following therapeutic failure with infliximab, 448  
exercise predictors and effects on symptoms, function and disease outcomes, 943  
fatigue measurement scales, 429  
finger tenosynovitis in untreated early RA, ultrasound vs. MRI diagnosis, 1158  
hand OA vs. RA, and health-related quality of life, 1404  
HAQ for estimating preference-based single indices in, 963  
herpes zoster risk in, 1431  
HLA-DRB1-related inflammation in cardiovascular mortality, 125  
inflammatory pseudotumor of liver in, 1102  
Joint Protection Behavior Assessment, German version, validation of, 249  
MDA and remission, preliminary definitions, 440  
MDA or remission, prevalence and long-term outcomes, 935  
medication usage, agreement between patient report and medical record review, 234  
Mindfulness-Based Stress Reduction, 1134  
new-onset, delay in consultation with specialist, 1419  
patient diaries, PDA vs. paper-pencil format, 454  
patient participation in self-management programs, 851  
power Doppler ultrasonography of joint inflammation, 116  
proposed revision to ACR20 criteria, 193  
recent-onset, and work disability in women, survival analysis, 372  
Rehabilitation Activities Profile effectiveness for structuring multidisciplinary team care, 240  
SF-36 physical functioning subscale vs. HAQ disability index for assessing, 723  
TNF $\alpha$  polymorphisms and response to etanercept therapy, 1426  
tolerance and effectiveness of anti-TNF $\alpha$  therapy in elderly patients, 679  
**Rheumatology**  
classification criteria for rheumatic diseases, 1112, 1119  
ILAR and global health initiatives, 885  
integration of evidence-based medicine into practice, 1116  
pediatric, improving training in, 1340  
Rasch analysis in outcomes measurement, 1358  
subspecialty choice, factors in, 1546  
**Risk factors**  
antioxidant and cardiovascular, in RA, 953  
atherosclerosis in GCA, 1481  
congestive heart failure, NSAIDs vs. COX-2 inhibitors, 516  
GCs and cardiovascular events, in PMR, 279  
herpes zoster risk in RA, DMARDs and, 1431  
HPV infections and cervical squamous intraepithelial lesions in SLE, 619  
OA, knee, prognostic factors for progression, 13

#### Risk factors (*cont'd*)

- racial/ethnic disparities in NSAID risk awareness, patient/doctor communication, and medicating behavior, 1539
- RA, DMARDs and septic arthritis development in, 1151
- tuberculosis and treatment with TNF antagonists, 756
- Rituximab
  - infusions for SS, 310
  - for refractory SLE, 538
- Rofecoxib, congestive heart failure risk, NSAIDs vs., 516

#### S

- Schmorl's nodes, genetics and lumbar disc disease, 855
- Scleroderma. *See* Systemic sclerosis (SSc)
- Scleroderma Gastrointestinal Tract 1.0 (SSC-GIT 1.0) survey, 1280
- Score for Assessment and Quantification of Chronic Rheumatoid Affections of the Hands (SACRAH), 1230
- Scoring. *See* Assessment; Measuring instruments
- SDI. *See* Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)
- Self-efficacy
  - dyadic efficacy of married women with RA and their spouses, 294
  - SLE, Medication Adherence Self-Report Inventory for measuring drug compliance, 1000
- Self-image
  - appearance and psychological distress in rheumatic diseases, 303
  - patient avoidance of total joint replacement for OA of hip or knee and, 27
- Self-management
  - arthritis patient participation in, 851
  - in integrated rehabilitation program for knee pain, 1211, 1220
  - OA, quality of life and primary care patient education, controlled trial, 1390
  - patient education for arthritis, 1081
  - RA, exercise predictors and effects on symptoms, function, and outcomes, 943
  - racial/ethnic disparities in NSAID risk awareness, patient/doctor communication, and medicating behavior, 1539
- Vasculitis Self-Management Scale, development and evaluation, 1296
- Self-report, agreement between RA patient report and medical record review for medications used, 234
- Septic arthritis, DMARDs and development of, 1151
- Short Form 6D (SF-6D)
  - knee OA, EQ-5D vs., in multiethnic Asian patients, 1043
  - RA, HAQ relationship with, 963
  - SLE, predicting damage accrual and mortality, 986
- Short Form 36 (SF-36)
  - coverage of concepts important to SLE patients, 1287
  - OA, long-term outcome of total hip replacement, 1375
  - physical functioning subscale vs. HAQ disability index for PsA and RA, 723
  - SF-6D vs., as SLE health status measure, 986
  - SSc, construct validity in, 94, 1339
- Shoulder, physical therapy following joint distension for adhesive capsulitis, efficacy and cost-effectiveness, 1027
- Siconolfi Step Test, for physical fitness assessment in SLE, 1007
- Silica exposure, in cement mason apprentices, 147
- Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY), 1165
- Sjögren's syndrome (SS)
  - B cell lymphoma and hepatitis C infection in, 161
  - neuromuscular biopsy for peripheral neuropathy diagnosis, 1520
  - rituximab infusions for, 310
- Skeletal abnormalities, hereditary multiple exostosis with JIA and brachydactyly, 1568
- SLE. *See* Systemic lupus erythematosus (SLE)
- Social factors, in juvenile FM in adolescents, 474
- Socioeconomic factors
  - in arthritis prevalence, 553
  - pulmonary disorders in SSc, GENISOS study, 318
- Socioeconomic factors (*cont'd*)
  - SLE, association with early disease damage, 993
  - SLE, in rheumatology subspecialty care utilization, 593
  - Spondylarthritis (SpA). *See also* Ankylosing spondylitis (AS)
    - accuracy of diagnoses in VA Medical Center databases, 648
    - effects of switching TNF $\alpha$  inhibitors for severe heel enthesitis in, 1572
  - Spondylarthritis Research Consortium of Canada (SPARCC), validation of MRI spinal inflammation index, 501
  - SS. *See* Sjögren's syndrome (SS)
  - SSc. *See* Systemic sclerosis (SSc)
  - Statins, adverse effects and malignant hyperthermia susceptibility, 186
  - Still's disease, adult-onset
    - IL-18 and apoptosis of peripheral blood leukocytes in, 1530
    - Parutscher-like retinopathy with thrombotic thrombocytopenic purpura in, 182
  - Streptococcal infections, in JIA flares, 877
  - Stress reduction
    - FM, mindfulness meditation for depression, 77
    - RA, mindfulness-based techniques, effectiveness of, 1134
  - Stroke, cerebrovascular, therapy in APS with aPL, 1487
  - Sulfasalazine, following intraarticular corticosteroids, vs. conservative treatment for early oligoarthritis, 154
  - Survivor analysis, recent-onset RA and work disability in women, 372
  - Symptom Limited Bicycle Ergometry test, 898
  - Synovectomy, for inflammatory arthritis in Norway, 529
  - Synovitis, absence in joint pain in Gulf War veterans' illness, 1316
  - Systemic Lupus Activity Measure, 1348
  - Systemic lupus erythematosus (SLE)
    - BMD in African American women with, 585
    - childhood-onset, validation of pediatric Automated Neuropsychological Assessment Metrics (Ped-ANAM), 1174
    - cognitive impairment in, factors affecting, 1461
    - coverage of concepts important to SLE patients by standard measures of disease activity and health status, 1287
    - cumulative indirect costs of, in US, Canada, and UK, 64
    - Devic's syndrome in, neuromyelitis optica IgG autoantibody testing for, 347
    - fatigue measurement in, 1348
    - HMO vs. fee-for-service impact on health care utilization, 508
    - HPV infection risk and cervical squamous intraepithelial lesions in, 619
    - LupusQOL measure for adults, development and validation, 972
    - Medicaid and access to care for, 601
    - Medication Adherence Self-Report Inventory for measuring drug compliance, 1000
    - memory impairment impact and employment status, 1453
    - multiethnic cohort modeling ethnic disparities in, 576
    - participation in atherosclerosis prevention trials in, factors determining, 49
    - pediatric, validation of pediatric SLE-specific health-related quality of life measure, 1165
    - peripheral blood leukocyte apoptosis and IL-18 in adult-onset Still's disease, 1530
    - physical fitness assessment with Siconolfi Step Test, 1007
    - progressive multifocal leukoencephalopathy in, differential diagnosis, 352
    - recruitment of subjects for clinical trials, 3
    - refractory, rituximab for, 538
    - relationship between appearance and psychological distress in, 303
    - rheumatology subspecialty care utilization, socioeconomic/demographic factors in, 593
    - sexual biology and age distribution in, 608
    - SF-6D predicting damage accrual and mortality in, 986
    - SLEQOL questionnaire, cross-cultural adaptation into Chinese, 980
    - sociodemographic associations with early disease damage, 993 in UK, 1990-1999, 612
    - whole blood viscosity and arterial thrombosis in, 845
    - work dynamics in persons with, 56

Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), 1348  
Systemic Lupus Erythematosus Quality of Life Questionnaire (SLEQOL), cross-cultural adaptation into Chinese, 980  
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)  
BMD in African American women with SLE, 585  
coverage of concepts important to SLE patients, 1287  
factors affecting severity of cognitive impairment, 1461  
sociodemographic associations with early disease damage, 993  
Systemic sclerosis (SSc)  
assessment of disability and quality of life, 94, 1339  
depression in, 1089  
gastrointestinal health-related quality of life instrument, development of, 1280  
health values of patients, 86  
juvenile, provisional classification criteria, 203  
pulmonary involvement in, GENISOS study, 318  
Systemic Sclerosis Health Assessment Questionnaire (SSc HAQ), construct validity of, 94, 1339

## T

Tai Chi, vs. hydrotherapy for OA, 407  
Tea, consumption and serum uric acid levels, 816  
Temporomandibular joint (TMJ), ultrasonography in JIA, 213  
Tenosynovitis, finger, in untreated early RA, 1158  
Terminology, RA MDA and remission, preliminary definitions, 440  
Thrombosis  
arterial, whole blood viscosity in SLE and, 845 therapy in APS with aPL, 1487  
Thrombotic thrombocytopenic purpura in adult-onset Still's disease, Purtscher-like retinopathy in, 182  
Time factors, delay in consultation with specialist in new-onset RA, 1419  
Tophus volume in gout, CT vs. physical measurement of, 461  
Treatment adherence  
JIA, caregiver recall of treatment recommendations, 219  
JIA, perceived, 226  
JIA, short-term outcomes in children and, 905  
SLE, Medication Adherence Self-Report Inventory for drug compliance, 1000  
Tuberculosis, treatment with TNF antagonists and risk of, 756  
Tumor necrosis factor (TNF). See also Anti-TNF therapy  
adverse effects identified from administrative claims data, 343  
babesiosis predisposition and TNF $\alpha$  blockade, 179  
TNF $\alpha$  polymorphisms and RA response to etanercept, 1426  
Twin studies  
Raynaud's phenomenon, vascular responsiveness to cold, 524  
Schmorl's nodes and lumbar disc disease, 855

## U

Ultrasonography  
MRI vs., for finger tenosynovitis diagnosis in untreated early RA, 1158  
power Doppler, for RA inflammation assessment, 116  
RA, relationship between clinical and imaging remission following anti-TNF therapy, 1564  
TMJ in JIA, 213  
United Kingdom (UK)  
cumulative indirect costs of SLE, 64  
SLE incidence, 1990-1999, 612  
United Kingdom General Practice Research Database, 1151

United States (US), cumulative indirect costs of SLE, 64  
Uric acid  
caffeine consumption and serum levels, 816  
optimal serum levels in gout, therapeutic target, 1324

## V

Vasculitis  
ANCA-associated small-vessel, self-management measure for, 1296  
Churg-Strauss syndrome, glucocorticoids with cyclophosphamide for, 686  
cutaneous, calciphylaxis vs., 533, 1575  
malignancies and, 1473  
necrotizing, in SS-related peripheral neuropathy, 1520  
pediatric WG, clinical features and outcomes, 837  
small-vessel and medium-vessel, 1552  
Vasculitis Self-Management Scale, 1296  
Venous thromboembolism, therapy in APS with aPL, 1487  
Vertebral end-plate, signal changes in chronic low back pain, 1311  
Veterans' health, absence of synovitis in joint pain in Gulf War veterans' illness, 1316  
Victorian Population Health Survey, arthritis prevalence, 553  
Visual analog scales (VAS), for fatigue measurement in RA, 429  
Vitamin D deficiency, cultural factors in, 1107  
Vitamin K<sub>2</sub>, for calciphylaxis, 1575  
Vocational rehabilitation, cost-utility analysis in chronic arthritis, 778

## W

Walking. See also Gait  
effects on knee joint structures in adults, 1261  
energy expenditure in RA vs. healthy controls, 672  
OA knee pain and mobility restrictions outside home, 1381  
Warfarin  
for APS, 1346  
for thrombosis in APS with aPL, 1487  
Wegener's granulomatosis (WG)  
malignancies associated with, 1473  
pediatric, clinical features and outcomes, 837  
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 633  
Whiplash injuries, early aggressive care and delayed recovery from, 861  
Whole blood viscosity, arterial thrombosis in SLE and, 845  
Wingate Anaerobic Exercise Test  
JIA, exercise capacity in adolescents, 898  
JIA, exercise capacity in children, 891  
Women  
OA, patella cartilage volume and bone volume, 272  
RA, dyadic efficacy of married women with their spouses, 294  
RA, recent-onset, work disability in, 372  
SLE, low BMD in African American women, 585  
Work disability  
arthritis and, 738  
arthritis-attributable, prevalence and correlates, 355  
cost-utility analysis of vocational rehabilitation, 778  
musculoskeletal, time course and effectiveness of interventions by diagnosis, 335  
RA, recent-onset, survival analysis in women, 372  
SLE, employment and productivity in, 56  
SLE, memory impairment and employment status, 1453  
work-related problems in inflammatory arthritis, 1269  
work-related repetitive stress injury and leisure-time physical activity, 495